```
cpgaacgtt.txt
```

```
? e au=krieg
Ref
     Items
             Index-term
             AU=KRIEFTEWIRTH, M.
E1
E2
             AU=KRIEFTEWIRTH, MICHAEL
        169
E3
             AU=KRIEG
E4
        374 AU=KRIEG A
Ē5
         84
             AU=KRIEG A F
E6
             AU=KRIEG A H
         12
E7
             AU=KRIEG A J
E8
        556
            AU=KRIEG A M
E9
        101
             AU=KRIEG A.
F10
         21
             AU=KRIEG A.F.
F11
          a
             AU=KRIEG A.H.
         25
E12
             AU=KRIEG A.J.
        595
E13
             AU=KRIEG A.M.
E14
             AU=KRIEG A.R.
E15
            AU=KRIEG A.S.
         25 AU=KRIEG ADAM J
E16
E17
         30 AU=KRIEG AF
E18
             AU=KRIEG AGOETTINGEN
E19
          6
             AU=KRIEG AH
E20
         11
             AU=KRIEG AJ
E21
         16
             AU=KRIEG ALEXANDER
E22
             AU=KRIEG ALEXYS R
E23
             AU=KRIEG ALOYS
E24
         14 AU=KRIEG ALOYSIUS
E25
        307 AU=KRIEG AM
          Enter PAGE for more
  s e3-e17, e25
                AU=KRIEG
          374
                AU=KRIEG A
           84
                AU=KRIEG A F
           12
                AU=KRIEG A H
            4
                AU=KRIEG A J
          556
                AU=KRIEG A M
          101
                AU=KRIEG A.
           21
                AU=KRIEG A.F.
            q
                AU=KRIEG A.H.
           25
                AU=KRIEG A.J.
          595
                AU=KRIEG A.M.
                AU=KRIEG A.R.
                AU=KRIEG A.S.
           25
                AU=KRIEG ADAM J
           30
                AU=KRIEG AF
          307
                AU=KRIEG AM
         2317
S1
                S E3-E17, E25
? s s1 and ((CpG or CG or immunostimulatory or nucleotide or oligo?)
>>>W: Unmatched parentheses
>>>E: There is no result
  s s1 and (CpG or CG or immunostimulatory or nucleotide or oligo?)
Processing
2317
122745
                S1
                CPG
        76559
                CG
        29315
                IMMUNOSTIMULATORY
      2606923
                NUCLEOTIDE
      2269833
                OLIGO?
S2
         1350
                S S1 AND (CPG OR CG OR IMMUNOSTIMULATORY OR NUCLEOTIDE OR OLIGO?)
```

```
ż
   rd
Processing
Processina
>>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S3
          444
               RD (UNIQUE ITEMS)
? s s3 and (palindrome or phosphorothioate)
444 S3
                 S3
          9434
                 PALINDROME
        49204
                 PHOSPHOROTHTOATE
S4
            92
                 S S3 AND (PALINDROME OR PHOSPHOROTHIOATE)
? d s
        Items
Set
                 Description
s1
          2317
                 S E3-E17, E25
S2
          1350
                 S S1 AND (CPG OR CG OR IMMUNOSTIMULATORY OR NUCLEOTIDE OR OLIGO?)
S3
           444
                     (unique items)
                 RD
54
            92
                 S S3 AND (PALINDROME OR PHOSPHOROTHIOATE)
?
  e au=steinberg
.
Ref
      Items Index-term
E1
             AU=STEINBERF R
E2
         573
            AU=STEINBERG
E3
             AU=STEINBERG
E4
              AU=STEINBERG , C. E. W.
Ē5
             AU=STEINBERG , J.
E6
             AU=STEINBERG , M. H.
E7
           ī
             AU=STEINBERG
E8
        506
             AU=STEINBERG A
Ē9
             AU=STEINBERG A A
Ē10
          12
             AU=STEINBERG A B
E11
             AU=STEINBERG A C
       1593 AU=STEINBERG A D
E12
E13
             AU=STEINBERG A D:
E14
             AU=STEINBERG A E
E15
        356 AU=STEINBERG A G
E16
          11
12
             AU=STEINBERG A H
E17
              AU=STEINBERG A I
E18
          18
             AU=STEINBERG A J
F19
             AU=STEINBERG A L
E20
        129
             AU=STEINBERG A M
E21
              AU=STEINBERG A N
E22
              AU=STEINBERG A O
E23
             AU=STEINBERG A P
E24
          16 AU=STEINBERG A S
E25
          11 AU=STEINBERG A W
           Enter PAGE for more
? s e2, e8-e25
           573
                 AU=STEINBERG
           506
                 AU=STEINBERG A
                 AU=STEINBERG A A
            12
                 AU=STEINBERG A B
                 AU=STEINBERG A C
          1593
                 AU=STEINBERG A D
                 AU=STEINBERG A D:
                 AU=STEINBERG A E
           356
                 AU=STEINBERG A G
            11
                 AU=STEINBERG A H
            12
```

AU=STEINBERG A I

```
cpgaacgtt.txt
           18
                AU=STEINBERG A J
                AU=STEINBERG A L
          129
                AU=STEINBERG A M
                AU=STEINBERG A N
                AU=STEINBERG A O
                AU=STEINBERG A P
                AU=STEINBERG A S
           16
           11
                AU=STEINBERG A W
S5
         3253
                S E2. E8-E25
? s s5 and (CPG OR CG OR IMMUNOSTIMULATORY OR NUCLEOTIDE OR OLIGO?)
         3253
                S5
       122745
                CPG
        76559
                CG
        29315
                IMMUNOSTIMULATORY
      2606923
                NUCLEOTIDE
      2269833
                OLIGO?
                S S5 AND (CPG OR CG OR IMMUNOSTIMULATORY OR NUCLEOTIDE OR OLIGO?)
56
? e e au=klinman
>>>W: = is in the wrong position for expand
  e au=klinman
?
Ref
     Items Index-term
E1
             AU=KLINMAHORM, S.
E2
            AU=KLINMALEE A.
E3
         42
           AU=KLINMAN
E4
             AU=KLINMAN C S
Ē5
         95
             AU=KLINMAN D
E6
             AU=KLINMAN D K
E7
        516
             AU=KLINMAN D M
E8
             AU=KLINMAN D M: HOFFMAN S L
Ē9
             AU=KLINMAN D R
Ē10
         63 AU=KLINMAN D.
E11
        472
            AU=KLINMAN D.M.
E12
             AU=KLINMAN D.R.
E13
          3 AU=KLINMAN DA
E14
         61 AU=KLINMAN DENNIS
E15
             AU=KLINMAN DENNIS A
E16
        298
             AU=KLINMAN DENNIS M
E17
             AU=KLINMAN DENNIS R
E18
        251
             AU=KLINMAN DM
E19
             AU=KLINMAN DN
E20
             AU=KLINMAN DP
E21
             AU=KLINMAN DR
E22
          5
           AU=KLINMAN J
E23
        354 AU=KLINMAN J P
E24
        10 AU=KLINMAN J. P. 373 AU=KLINMAN J.P.
F25
          Enter PAGE for more
? s e3, e14-e21
           42
                AU=KLINMAN
           61
                AU=KLINMAN DENNIS
                AU=KLINMAN DENNIS A
          298
                AU=KLINMAN DENNIS M
                AU=KLINMAN DENNIS R
            1
          251
                AU=KLINMAN DM
                AU=KLINMAN DN
                AU=KLINMAN DP
            1
                AU=KLINMAN DR
S7
          658
                S E3. E14-E21
```

Page 3

```
cpgaacgtt.txt
? s s7 and (CPG OR CG OR IMMUNOSTIMULATORY OR NUCLEOTIDE OR OLIGO?)
           658
                  S7
        122745
                  CPG
         76559
                  CG
         29315
                  IMMUNOSTIMULATORY
       2606923
                  NUCLEOTIDE
       2269833
                  OLTGO?
58
           373
                  S S7 AND (CPG OR CG OR IMMUNOSTIMULATORY OR NUCLEOTIDE OR OLIGO?)
  s AACGTT
           256
                  S AACGTT
? s s1 and (lip?)
Processing
Processing
           256
                  S1
                  LIP?
       5876822
S2
                  S S1 AND (LIP?)
  s s1 and (oligonucleotide or antisense or sequence or dinucleotide or
immunostimulatory)
Processing
           256
                  s1
        500609
                  OLIGONUCLEOTIDE
        315122
                  ANTISENSE
       6782267
                  SEQUENCE
        205908
                  DINUCLEOTIDE
         30530
                  IMMUNOSTIMULATORY
           238
                  S S1 AND (OLIGONUCLEOTIDE OR ANTISENSE OR SEQUENCE OR DINUCLEOTIDE
OR IMMUNOSTIMULATORY)
>>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
            56 RD (UNIQUE ITEMS)
? t s4/3.k/1-54
>>>W: KWIC option is not available in file(s): 399
 4/3,K/1 (Item 1 from file: 5) Links
Fulltext available through: STIC
                                     STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.
0020635128 Biosis No.: 200800682067
The effects of local DNA sequence on the interaction of ligands with their preferred
binding sites
Author: Hampshire Andrew J; Fox Keith R (Reprint)
Author Address: Univ Southampton, Sch Biol Sci. Bassett Crescent E. Southampton SO16
7PX, Hants, UK**UK
Author E-mail Address: k.r.fox@soton.ac.uk
Journal: Blochimie (Paris) 90 (7): p 988-998 JUL 2008 2008
Item Identifier: doi:10.1016/j.biochi.2008.01.001
ISSN: 0300-9084
Document Type: Article
Record Type: Abstract
Language: English
The effects of local DNA sequence on the interaction of ligands with their preferred
binding sites
```

cpgaacgtt.txt Abstract: We have examined the effects of local DNA sequence on the interaction of distamycin, Hoechst 33258, echinomycin, actinomycin and mithramycin with their distamyCin, Hoecnst 33228, echinomyCin, actinomyCin and mithramyCin with their preferred binding sites using a series of DNA fragments that contain every symmetrical hexanucleotide sequence. In several instances we find that the affinity for the ligands' preferred binding sites is....yet shows no binding to TTCGAA, TCCGCA and AGCGCT, while the best binding is to AACGTT. The tetranucleotides CCGG and ACCT produce consistently good binding sites, irrespective of the surrounding sequences...to all the potential symmetrical hexanucleotides and provide insights into the effects of local DNA sequence on ligand-DNA interactions. (C) 2008 Elsevier Masson SAS, All rights reserved.

4/3,K/2 (Item 2 from file: 5) Links Fulltext available through: STIC STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved.

0020364532 Biosis No.: 200800411471
The expression profile of TLR9 mRNA and CpG ODNs immunostimulatory actions in the teleost gilthead seabream points to a major role of lymphocytes

Author: Cuesta A (Reprint); Esteban M A; Meseguer J Author Address: Univ Murcia, Fac Biol, Dept Cell Biol and Histol, Fish Innate Immune Syst Grp, E-30100 Murcia, Spain**Spain Author E-mail Address: cuesta.alberto@inia.es Journal: Cellular and Molecular Life Sciences 65 (13): p 2091-2104 JUL 2008 2008

Item Identifier: doi:10.1007/s00018-008-8146-7

ISSN: 1420-682X Document Type: Article Record Type: Abstract Language: English

The expression profile of TLR9 mRNA and CpG ODNs immunostimulatory actions in the teleost gilthead seabream points to a major role of lymphocytes

Abstract: ...cell-source. To conclude, ODNs containing GACGTT, GTCGTT (optimal for mouse and human, respectively) or AACGTT motifs are the most potent inducers of seabream immunity, whilst the involvement of TLR9 is... DESCRIPTORS:

Miscellaneous Terms: Concept Codes: ...immunostimulatory action

4/3,K/3 (Item 3 from file: 5) Links Fulltext available through: STIC STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation, All rights reserved.

18218711 Biosis No.: 200500125776

DNA structure constraint is probably a fundamental factor inducing CpG deficiency in bacteria

Author: Wang Yong: Leung Frederick C C (Reprint) Author Address: Dept Zool, Univ Hong Kong, Hong Kong, Hong Kong, China**China Author E-mail Address: fcleung@hkucc.hku.hk Journal: Bioinformatics (Oxford) 20 (18): p 3336-3345 December 12, 2004 2004 Medium: print ISSN: 1367-4803

Document Type: Article Record Type: Abstract

Language: English

Abstract: Motivation: It has been speculated that CpG dinucleotide deficiency in genomes is a consequence of DNA methylation. However, this hypothesis does not adequately....the TTCGAA pattern, was under represented in low GC content Page 5

bacterial genomes regardless of CpG dinucleotide level. This is in contrast to the AACGTT pattern, indicating that the counterselection is context-dependent. Further study discovered nine underrepresented patterns that.....proposed for the strong correlation between GC content and CpG deficiency. The result of random sequence simulation showed that the occurrences of these patterns were correlated with GC content, as well...
DESCRIPTORS Biochemicals: AACGTT;CpG dinucleotide—Methods & Equipment: sequence simulation...
Geographical Name:

4/3,K/4 (Item 4 from file: 5) Links

4/3,K/4 (Item 4 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.
17222739 Biosis No.: 200300181458
CpG oligodeoxynucleotides activate grass carp (Ctenopharyngodon idellus)
macrophages.

Author: Meng Zhen; Shao Jianzhong (Reprint); Xiang Lixin
Author Address: College of Life Sciences, Zhejiang University, Hangzhou, 310012,
China** China
Author E-mail Address: lscshaoj@mail.hz.zj.cn
Journal: Developmental and Comparative Immunology 27 (4): p 313-321 April 2003
2003
Medium: print

Medium: print ISSN: 0145-305X Document Type: Article Record Type: Abstract Language: English

Abstract: ...ODN-1826 (GACGTT) and -2006 (GTCGTT) for the mice and humans cells, the ODN-1670 (AACGTT) used in Atlantic salmon, the ODN-D containing two repeats motif of those in 1670. ... found and the ODN-D was not more efficient than 1670. It suggests that the sequence which contains the unmentylated 'GG' dinuclocities could make contribute to this immunostimulatory effect. These findings indicate that CGG-ODNs could be useful tools for understanding the important...

4/3,K/S (Item 5 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(C) 2009 The Thomson Corporation. All rights reserved.
16834896 Biosis No.: 200200428407
DNA sequence recognition of thiazole-containing cross-linked polyamides can be favored by T-A steps

Author: Burckhardt G (Reprint); Simon H (Reprint); Birch-Hirschfeld E; Kittler L; Sharma S K; Lown J W; Zimmer C (Reprint) Author Address: Institut fuer Molekularbiologie, Friedrich-Schiller-Universitaet (FSU) Jena, Winzerlaer Str. 10, D-07745, Jena, Germany**Germany Journal: Journal of Biomolecular Structure and Dynamics 19 (6): p 1101-1109 June, 2002 2002

Medium: print ISSN: 0739-1102 Document Type: Article

Record Type: Article Racord Type: Abstract Language: English

DNA sequence recognition of thiazole-containing cross-linked polyamides can be favored by T-A steps

Abstract: The binding ability of cross-linked thiazolated polyamides (containing the base sequence-reading elements thiazole(Th)-pyrrole(Py)-pyr-role(Py) and thiazole(Th)-imidazole(Im)-pyrrol.....concentration demonstrate that the dimers with a heptanediyl linker (C7 dimer) show a significantly higher sequence specificity than their corresponding monomers. The dimer of Th-Py-Py primarily Gpair within the central sequence (e.g. AAGGTT). Surprisingly, the sequence binding ability is strongly influenced by the presence of a T-A step: e.g.....of the cross-linked dimer to the minor groove is discussed in light of the sequence PESCRIPTORS:

Chemicals & Biochemicals: ...DNA sequence recognition

4/3,K/6 (Item 6 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16222243 Biosis No.: 200100394082 Immunostimul latory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages

Author: Shoda Lisl K M; Kegerreis Kimberly A; Suarez Carlos E; Mwangi Waithaka; Knowles Donald P; Brown Wendy C (Reprint) Author Address: Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, 99164-7040, USA**USA Journal: Journal of Leukocyte Biology 70 (1): p 103-112 July, 2001 2001 Medium: print ISSN: 0741-5400 Document Type: Article Record Type: Abstract Language: English Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages

Abstract: ...plasmid DNA (DDNA) for B lymphocytes and professional antigen-presenting cells. In mice, modification of immunostimulatory sequences (ISSs), including CpG motifs, in pDNA vectors or oligodeoxynucleotides can increase or decrease their....murrine and human leukocytes. We have previously characterized the mitogenic properties of oligodeoxynucleotides containing one AACGIT motif for bovine B lymphocytes. We now define cytokine responses by macrophages stimulated with pDNA engineered to contain an ISS comprising two AACGIT motifs. Macrophages activated with CpG-modified pDNA secreted significantly more interleukin-12, tumor necrosis factor...

Chemicals & Biochemicals: ...immunostimulatory CpG-modified plasmid DNA

4/3,K/7 (Item 7 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(C) 2009 The Thomson Corporation. All rights reserved.
16068303 Biosis No.: 200100240142

Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens

Author: Musacchio Alexis (Reprint); Rodriguez Ernesto G; Herrera Antonieta M; Quintana Diogenes; Muzio Verena Author Address: Vaccine Division, Center for Genetic Engineering and Biotechnology of Havana, Havana, 10 600, cuba-*cuba Journal: Biochemical and Biophysical Research Communications 282 (2): p 442-446 March 30, 2001 2001

Medium: print ISSN: 0006-291X Document Type: Article Record Type: Abstract Language: English

Abstract: ...100 mug of each construct, either alone or in combination. In spite of lacking known immunostimulatory sequences (e.g., AAGGTT), significant cellular (proliferative) and humoral immune responses were raised against both antigens. Coadministration of both.... of the antigen expression and further immune response, by using the Kozak's translation initiation sequence, was also analyzed. No differences due to its presence or absence were observed.

4/3,K/8 (Item 8 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.
15665643 Biosis No.: 200000383956
Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes

Author: Fujieda Shigeharu (Reprint); Iho Sumiko; Kimura Yuichi; Yamamoto Hideyuki; Igawa Hideki; Saito Hitoshi Author Address: Department of Otorhinolaryngology, Fukui Medical University, Shimoaizuki, Matsuoka, Yoshida, Fukui, 910-1193, Japan*Japan Journal: American Journal of Respiratory and Critical Care Medicine 162 (1): p 232-239 July, 2000 2000 Medium: print

Medium: print ISSN: 1073-449x Document Type: Article Record Type: Abstract Language: English

Abstract: ...the MPB-70 of Mycobacterium bovis Bacillus Calmette-Guerin. Two ODNs, containing CGT-ACG or AACGTT inhibited IgE production by human PBMC. When other oligonucleotides were substituted in a portion of the sequence of the core or flanking oligonucleotides in the ODN containing CGTACG, ODNs containing NACGTTCG or...

4/3,K/9 (Item 9 from file: 5) Links Fulltext available through: STIC Full Text Retrieval Options Blosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. 15386572 Blosis No.: 200000104885 Modulation of host immune responses by protozoal DNA

Author: Brown Wendy C (Reprint); Suarez Carlos E; Shoda Lisl KM; Estes D Mark Author Address: Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, 99164-7040, USA**USA Journal: Veterinary Immunology and Immunopathology 72 (1-2): p 87-94 Dec. 15, 1999 1999 Medium: print ISSN: 0165-2427 Document Type: Article; Literature Review

Document Type: Article; Literature Review Record Type: Abstract Language: English

Abstract: ...IgG secretion by cultured B cells, stimulating IgGL and more strongly, IgG2. Several hexameric CpG immunostimulatory sequences (ISS) active for murine B cells were identified in an 11 kb fragment of B. bovis DNA. An oligodeoxyribonucleotide containing one of these (AACGIT), located in the rhoptry associated protein-l (rap-1) open reading frame, stimulated B cell...

DESCRIPTORS:
Chemicals & Biochemicals: ...immunostimulatory sequences

4/3,K/10 (Item 10 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Blosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.
15331378 Blosis No.: 200000049691
Influence of backbone chemistry on immune activation by synthetic oligonucleotides

Author: Pisetsky David S (Reprint); Reich Charles F III
Author Address: VA Medical Center, 508 Fulton St., Durham, NC, USA**USA
Journal: Biochemical Pharmacology
Medium: print
ISSN: 0006-2952
Document Type: Article
Record Type: Abstract

Abstract: Depending on base sequence, DNA displays immunological activities relevant to the design of novel therapeutic agents. To determine the.....These compounds were 30 bases long and consisted of either a single base or an immunostimulatory sequence (AACGTT) flanked on 5' and 3' ends by 12 nucleotides of each base. Cell activation was....and cytokine production than the comparable phosphodiester compounds and had activity at lower concentrations. The sequence for optimal stimulation by phosphorothioates varied among responses, however. For example, whereas compounds containing an immunostimulatory sequence all index example and the comparable phosphodiester some production. Together, these findings indicate that base sequence as well as backbone chemistry influence immune activation by synthetic oligonucleotides, with the effects varying...

4/3, K/11 (Item 11 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.
15169085 Biosis No.: 199900428745
The effect of COS Sequences on the R cell response to a viral gly

The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector $\,$

Author: Pasquini S; Deng H; Reddy S T; Giles-Davis W; Ertl H C J (Reprint) Author Address: Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA**USA Journal: Gene Therapy 6 (8): p 1448-1455 Aug., 1999 1999

Journal Gene Herapy 6 (8), p 1448-1433 Aug., 1999 I Medium: print ISSN: 0969-7128

ISSN: 0969-7128 Document Type: Article Record Type: Abstract Language: English

Language: English

Abstract: ...product in mice. The antibody response could be rescued by concomitant injection of oligonucleotides carrying immunostimulatory sequences. The B cell response to two plasmid vectors, both expressing the same viral glycoprotein but containing a different content of the highly stimulatory AACGT motif, was compared. Comparable B cell responses were induced to the two constructs given at...

4/3,K/12 (Item 12 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

```
14989425 Biosis No.: 199900249085
Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have
an effect on the immunogenicity of DNA and subunit vaccines in fish
Author: Kanellos T S; Sylvester I D; Butler V L; Ambali A G; Partidos C D; Hamblin A
S; Russell P H (Reprint)
Author Address: Department of Pathology and Infectious Diseases, Royal Veterinary
College, Royal College Street, London, Nw1 OTY, UK**UK
Journal: Immunology 96 (4): p 507-510 April, 1999 1999
Medium: print
ISSN: 0019-2805
Document Type: Article
Record Type: Abstract
Language: English
Abstract: A eukaryotic plasmid DNA carrying the AACGTT CpG motif in its ampR gene is
a 'danger' signal for mice and caused an... ... no effect on antibody responses to
beta-gal in either fish or mice. A synthetic oligonucleotide, which contains the
GACGTT motif, potentiated antibody responses to co-administered beta-gal protein
in...
 4/3,K/13 (Item 13 from file: 5) Links
    Fulltext available through:
                                        STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.
14717222 Biosis No.: 199800511469
DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B
cells.
Author: Brown Wendy C (Reprint): Estes D Mark: Chantler Sue Ellen: Kegerreis
Kimberly A; Suarez Carlos E
Author Address: Dep. Vet. Microbiol. Pathol., Washington State Univ., Pullman, WA
99164-7040, USA**USA
Journal: Infection and Immunity 66 (11): p 5423-5432 Nov., 1998 1998
Medium: print
ISSN: 0019-9567
Document Type: Article
Record Type: Abstract
Language: English
DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B
cells
Abstract: ...human B cells, an 11-kb fragment of B. bovis DNA was analyzed for CG dinucleotide content and for the presence of known immunostimulatory sequences (Total Content on a CG motif. The frequency of CG dinucleotides was approximately one... ...known activity for murine B cells were identified. An oligodeoxynucleotide containing one of these ISS (AAGGTT), which is present within the rhoptry-associated protein-1 (rap-1) open reading frame, was...
DESCRIPTORS:
 Chemicals & Biochemicals: CpG oligonucleotide; ... ...immunostimulatory sequences
 4/3,K/14 (Item 14 from file: 5) Links
    Fulltext available through:
                                        STIC Full Text Retrieval Options
```

(c) 2009 The Thomson Corporation. All rights reserved.

Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in

(c) 2009 The Thomson Corporation. All rights reserved. 14060235 Biosis No.: 199799694295

Biosis Previews(R)

rodents

cpgaacgtt.txt Author: Monteith David K (Reprint): Henry Scott P: Howard Randy B: Flournoy Shin: Levin Arthur A; Bennett C Frank; Crooke Stanley T Author Address: Isis Pharmaceuticals, 2292 Faraday Ave., Carlsbad, CA 92008, USA**USA Journal: Anti-Cancer Drug Design 12 (5): p 421-432 1997 1997 ISSN: 0266-9536 Document Type: Article Record Type: Abstract Language: English Abstract: ...B-lymphocyte proliferation in vitro and splenomegaly correlated well for the oligodeoxynucleotides tested. Particular oligodeoxynucleotide sequence motifs or palindromes have been demonstrated to affect in vitro cell proliferation. Inclusion of a 5'-AACGTT-3' palindrome in a phosphorothioate oligodeoxynucleotide sequence significantly enhanced the potency. While inclusion of this palindrome or a CpG motif alone may... 4/3,K/15 (Item 15 from file: 5) Links Fulltext available through: STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. 13684118 Biosis No.: 199799318178 Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon Author: Sonehara Kazuhiko; Saito Hitoshi; Kuramoto Etsuro (Reprint); Yamamoto Saburo; Yamamoto Toshiko; Tokunaga Tohru Author Address: Inst. Biological Science, Mitsui Pharmaceuticals Inc., 1900-1 Togo. Mobara, Chiba 297, Japan**Japan Journal: Journal of Interferon and Cytokine Research 16 (10): p 799-803 1996 1996 ISSN: 1079-9907 Document Type: Article Record Type: Abstract Language: English Abstract: ...cells, and thus exhibit tumor-regressing activity. The present study showed that a hexamer palindromic oligonucleotide (5'-AACGTT -3') alone induced IFN from mouse spleen cells when added with cationic liposomes. Accordingly, 32... ...the activity. No hexamer oligonucleotides showed the activity when liposomes were absent. A complete palindromic sequence was essential as any single base substitution resulted in diminished activity. Among variety of palindromic oligonucleotides of different sizes with an ACGT sequence at the center, the tetramer oligonucleotide was without activity, whereas the activity of hexamer and longer oligonucleotides was almost equally high... ..strongly suggest that the minimal essential structure required for IFN induction is the hexamer palindromic sequence with C6 moriffs) sequence with CG motif(s). 4/3.K/16 (Item 16 from file: 5) Links Fulltext available through: STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. 12654035 Biosis No.: 199598121868 Myb proteins 'talking' to their DNA (review) Author: Boulikas Teni Author Address: Inst. Molecular Med. Sci., 460 Page Mill Road, Palo Alto, CA 94306. USA** USA Journal: International Journal of Oncology 5 (1): p 101-109 1994 1994 ISSN: 1019-6439

Page 11

Document Type: Article; Literature Review

Record Type: Abstract Language: English

Abstract: DNA sequence-specific proteins called transcription factors found in all multicellular organisms control the expression of genes....mammals including humans, plants, flies, Dictyostelium, and yeast. Myb proteins show a preference for the AACGTT, AACnGTT and the AA-C-TAAC-T-GGAA motifs with AAC (or its complementary GTT.

GTT... 4/3,K/17 (Item 17 from file: 5) Links Fulltext available through: STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. 12605903 Biosis No.: 19598073736 Binding of Oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN Author: Kimura Yoshimitsu (Reprint); Sonehara Kazuhiko (Reprint); Kuramoto Etsuro (Reprint); Makino Tadashi; Yamamoto Saburo; Yamamoto Toshiko; Kataoka Tetsuro; Tokunaga Tohru Author Address: Inst. Biological Sci., Mitsui Pharmaceuticals Inc., 1900-1 Togo, Mobara, Chiba 297, Japan**Japan Journal: Journal of Biochemistry (Tokyo) 116 (5): p 991-994 1994 1994 ISSN: 0021-924X Document Type: Article Record Type: Abstract Language: English Abstract: ...sequences, we investigated the possible target molecules of the oligonucleotides. Oligo-II, a30mer Single-stranded oligonucleotide with oligoG sequences next to the active palindromic sequence (AACGT), had more activity than oligonucleotides with oligoA, oligoC, or oligoT sequences. The activity of oligo... in the scavenger receptor on mouse splenocytes. These findings suggest that the binding of an extrapalindromic sequence to the scavenger receptor is required for the immunostimulatory activity of oligo-1. DESCRIPTORS: Miscellaneous Terms: Concept Codes: ...PALINDROMIC SEQUENCE 4/3,K/18 (Item 18 from file: 5) Links Fulltext available through: STIC Fo STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. 12542786 Biosis No.: 199598010619 Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity

Author: Yamamoto Toshiko (Reprint); Yamamoto Saburo; Kataoka Tetsuro; Tokunaga Tohru

Author Address: Dep. Bacterial Blood Products, Natl. Inst. Health, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208, Japan**Japan Journal: Microbiology and Immunology 38 (10): p 831-836 1994 1994 ISSN: 0385-5600 Document Type: Article

Record Type: Article
Language: English

Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGT to murine splenocytes enhances interferon production and natural killer activity

Abstract: A synthetic 22-mer oligodeoxyribonucleotide having an AACGTT palindrome. AAC-22, induced interferon (IFN) production and augmented the natural killer (NK) activity in...

4/3,K/19 (Item 19 from file: 5) Links Fulltext available through: STIC Full Text Retrieval Options Biosis Previews(R)

(c) 2009 The Thomson Corporation, All rights reserved.

12491543 Biosis No.: 199497512828

Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro

Author: Yamamoto Toshiko (Reprint); Yamamoto Saburo (Reprint); Kataoka Tetsuro (Reprint); Komuro Katsutoshi (Reprint); Kohase Masayoshi; Tokunaga Tohru Author Address: Dep. Bacterial Blood Products, Natl. Inst. Health, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208, Japan**Japan Journal: Japanese Journal of Cancer Research 85 (8): p 775-779 1994 1994 ISSN: 0910-5050 Document Type: Article

Record Type: Abstract Language: English

Abstract: ...of synthetic single-stranded 30-mer oligodeoxyribonucleotides (oligoDNAs) with three different kinds of hexamer palindromic sequence to induce interferon (IFN) production of human peripheral blood lymphocytes (PBL). When PBL was cultured with oligoDNA having a palindrome of AACGTT or GACGTC, IFN activity was detected by bioassay in the culture fluid after 8 h...

4/3,K/20 (Item 20 from file: 5) Links Fulltext available through: STIC F STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. Biosis No.: 199294060868

UNIQUE PALINDROMIC SEQUENCES IN SYNTHETIC OLIGONUCLEOTIDES ARE REQUIRED TO INDUCE

INF AND AUGMENT INF-MEDIATED NATURAL KILLER ACTIVITY

Author: YAMAMOTO S (Reprint); YAMAMOTO T; KATAOKA T; KURAMOTO E; YANO O; TOKUNAGA T AUTHOR Address: DEP CELLULAR IMMUNOLOGY, NATIONAL INSTITUTE HEALTH, 2-10-35 KAMIOHSAKI, SHINAGAWA-KU, TOKYO 141, JPN**JAPAN JOURNAL: Journal of Immunology 148 (12): p 4072-4076 1992

ISSN: 0022-1767

Document Type: Article Record Type: Abstract Language: ENGLISH

Abstract: Thirty-mer single-stranded oligonucleotides, with a sequence chosen from the known CDNA encoding the 64-kba protein named 40 A or the.....cell activity of mouse spleen cells by coincubation in vitro. Three with the hexamer palindromic sequence as GACGTC were active, whereas two kinds of oligonucleotides with noo palindrome were inactive. The.....least one of the different palindromic sequences showed no activity, when a portion of the sequence of the inactive oligonucleotides was substituted with either palindromic sequence of GACGTC, AGCGCT, or AACGTT, the oligonucleotide acquired the ability to augment NK activity. In contrast, the oligonucleotides substituted with another palindromic sequence such as ACCGGT was without effect. Furthermore, exchange of two neighboring mononuclectides within, but not outside, the active palindromic sequence destroyed the ability of the oligonuclectides to augment NK cell activity. Stimulatino of spleen cells with the substituted oligonucleotide, A4a-AAc, induced production of significant amounts of IFN-.ajpha./.beta.amd small amounts of IFN-.gamma. Augmentation of NK activity of the cells by the oligonucleotide was ascribed to IFN-.alpha./.beta. production. These results strongly suggest that the presence of the unique panlindromic

cpgaacgtt.txt sequences, such as GACGTC, AGCGCT, and AACGTT, but not ACCGGT, is essential for the immunostimulatory activity of oligonucleotides.

4/3,K/21 (Item 21 from file: 5) Links Fulltext available through: STIC Full Text Retrieval Options Biosis Previews(R) (c) 2009 The Thomson Corporation. All rights reserved. 10880479 Biosis No.: 199192126250 INTERACTION OF THE V-MYB AND C-MYB PROTEINS WITH REGULATORY SEQUENCES OF THE HUMAN C-MYC GENE

Author: ZOBEL A (Reprint); KALKBRENNER F; GUEHMANN S; NAWRATH M; VORBRUEGGEN G; MOELLING K Author Address: MAX-PLANCK-INST MOLEKULARE GENETIK, ABT SCHUSTER, IHNESTRASSE 73, D-1000 BERLIN 33, GER**GERMANY Journal: Oncogené 6 (8): p 1397-1408 1991 ISSN: 0950-9232 Document Type: Article Record Type: Abstract Language: ENGLISH

Abstract: ...different affinities whereby strong binding correlates better with conservation of the palindromic sequences, AACXGTT or AACGTT, than the previously described consensus sequence. Flanking AT-rich sequences further increase the binding affinity. The c-Myb-binding sites are.. DESCRIPTORS: ONCOGENES NUCLEOTIDE SEQUENCE MOLECULAR SEQUENCE DATA GENE EXPRESSION

4/3,K/22 (Item 1 from file: 24) Links Fulltext available through: STIC F STIC Full Text Retrieval Options CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved. 0002443079 IP Accession No: 5551323 Effect of hsp65 DNA vaccination carrying immunostimulatory DNA sequences (CpG motifs) against Mycobacterium leprae multiplication in mice

Nomaguchi, H; Mukai, T; Takeshita, F; Matsuoka, M; Maeda, Y; Aye, TM; Jahan, N; Yogi, Y; Sato, MEY; Makino, M* Leprosy Research Center, National Institute of Infectious Diseases, 4-2-1-Aobacho, Higashimurayma, Tokyo 189-0002, Japan, [mailto:mmaki@nih.go.jp] International Journal of Leprosy and Other Mycobacterial Diseases , v 70 , n 3 , p 182-190 , September 2002 Publication Date: 2002

Document Type: Journal Article Record Type: Abstract Language: English Summary Language: English; Spanish; French ISSN: 0148-916X File Segment: Bacteriology Abstracts (Microbiology B) Effect of hsp65 DNA vaccination carrying immunostimulatory DNA sequences (CpG motifs) against Mycobacterium leprae multiplication in mice

Abstract: ...and humoral antigen (Aq)-specific immune responses. It has been reported that palindromic, single stranded immunostimulatory DNA sequences (ISS) induce production of IFN- alpha, IFN- beta and IFN- gamma by murineISS include the palindromic Coc-containing hexamers: 5'-GACGTC-3', 5'-AACGTC-3', and 5'-AACGTT-3'. Recently, Sato, et al., reported that a pDNA expression vector (pACB) containing two repeats of 5'- AACGTT-3' in the ampR gene is highly immunogenic, because it elicits

```
strong Ag-specific immunity...
Identifiers: Immunostimulatory DNA sequences
Subi Cata:
 4/3,K/23 (Item 2 from file: 24) Links
   Fulltext available through:
                                    STIC Full Text Retrieval Options
CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved.
0002405727
                IP Accession No: 5726736
Enhanced cell-mediated_IFN- gamma -secreting activity against the HIV-1IIIB V3
peptide of the TAB9 multiepitope after DNA vaccine backbone engineering
Rodriguez, EG*; Vazquez, DM; Herrera, AM; Duarte, CA Vaccine Division, Center for Genetic Engineering and Biotechnology of Havana, P.O. Box 6162, Havana 10600, Cuba,
[mailto:ernesto.galban@cigb.edu.cu]
Biochemical and Biophysical Research Communications . v 308 . n 4 . p 713-718 .
September 5, 2003
Publication Date: 2003
Publisher: Elsevier Inc.
Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 0006-291X
File Segment: Nucleic Acids Abstracts; Virology & AIDS Abstracts
Abstract:
...globin-based termination/polyadenylation sequences, and 5, 10, and 20 copies of the 5 super()-AACGTT-3 super() CpG motif were inserted. Balb/c mice were immunized
by intramuscular injection of...
Descriptors: Repeated sequence; Genetic engineering; Antigens; DNA viruses;
Plasmids; Epitopes; gamma -Interferon; Immunoglobulin G; Expression vectors;
Polvadenvlation: DNA...
Tdentifiers:
 4/3,K/24 (Item 3 from file: 24) Links
   Fulltext available through:
                                    STIC Full Text Retrieval Options
CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved.
0002111341
                IP Accession No: 4758218
DNA Sequence Recognition of a Cross-Linked Polyamide: CD Studies, Footprinting and
Effects on the Activity of DNA Gyrase
Burckhardt, G; Foertsch, I; Simon, H; Birch-Hirschfeld, E; Kittler, L; Schuetz, H;
Sharma, SK; Lown, JW; Zimmer, C Institut fuer Molekularbiologie der
Friedrich-Schiller-Universitaet (FSU) Jena, Winzerlaer Str. 10, D-07745 Jena,
Germany, [mailto:christoph.zimmer@rz.uni-jena.de]
Editor: Sarma, RH; Sarma, MH (eds)
Journal of Biomolecular Structure and Dynamics . v 11 . n 2 . p 355-363 . March 28.
2000
Publication Date: 2000
Publisher: Adenine Press, 2066 Central Avenue Schenectady NY 12304 USA
Conference:
Proc. 11th Conversation in Biomolecular Stereodynamics, Albany, NY (USA), 15-19 Jun
```

Document Type: Journal Article; Conference Page 15

Record Type: Abstract Language: English Summary Language: English ISSN: 0739-1102

File Segment: Nucleic Acids Abstracts

DNA Sequence Recognition of a Cross-Linked Polyamide: CD Studies, Footprinting and Effects on the Activity of ...

Abstract:

...a clear-cut different binding tendency to various dodecamers at 2 M NaCl indicating that sequence specificity becomes apparent at high salt concentration. The highest binding preference occurs to the dodecamers with the central sequences: AACGTT, AAGTTT and ATCGTA but almost no affinity was observed at 2 M NaCl for ACGGCT, ATCGAT and AAATTT. From the results it appears that the sequence selectivity of the dimer can be ascribed to the side-by-side binding mode of...

4/3,K/25 (Item 4 from file: 24) Links Fulltext available through: STIC Full Text Retrieval Options CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved. 0002018988 IP Accession No: 4634558

Presence of CpG DNA and the Local Cytokine Milieu Determine the Efficacy of Suppressive DNA Vaccination in Experimental Autoimmune Encephalomyelitis

Lobell, A; Weissert, R; Eltayeb, S; Svanholm, C; Olsson, T; Wigzell, H Microbiology and Tumorbiology Center, Karolinska Institute, Box 280, S-171 77 Stockholm, Sweden, [mailto:Anna.Lobel]@mtt.ki.sel Journal of Immunology, v 163, n 9, p 4754-4762, November 1, 1999 Publication Date: 1999

Document Type: Journal Article Record Type: Abstract Language: English Summary Language: English ISSN: 0022-1767

File Segment: Immunology Abstracts: Medical & Pharmaceutical Biotechnology Abstracts

Abstract:

We here study the adjuvant properties of immunostimulatory DNA sequences (ISS) and coinjected cytokine-coding CDNA in suppressive vaccination with DNA encoding an...
...necessary for efficient DNA vaccination, we studied the effect of one such ISS, the 5'-AcGTT-3' motif, in our system. Treatment with a DNA vaccine encoding myelin basic protein peptide 68-85 and containing three ISS of 5'-AcGTT-3' sequence suppressed clinical signs of EAE, while a corresponding DNA vaccine without such ISS had no...

Descriptors: ...colony-stimulating factor; Tumor necrosis factor- alpha; Myelin basic protein; Vaccines; Cytokines; Experimental allergic encephalomyelitis; immunostimulatory DNA sequences; DNA vaccines Identifiers:

4/3,K/26 (Item 5 from file: 24) Links Fulltext available through: STIC Full Text Retrieval Options CSA Life Sciences Abstracts (c) 2009 CSA. All rights reserved. 0001556843 IP Accession No: 3830608

Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length Page 16

Yamamoto, T; Yamamoto, S; Kataoka, T; Tokunaga, T Dep. Bact. and Blood Prod., Natl. Inst. Health, Gakuen, 4-7-1, Musashi-Murayama-shi, Tokyo 208, Japan ANTISENSE RES. DEV., v 4 , n 2 , p 119-122 , 1994 Addl. Source Info: ANTISENSE RES. DEV., vol. 4, no. 2, pp. 119-122, 1994 Publication Date: 1994

Document Type: Journal Article Record Type: Abstract Language: English Summary Language: English ISSN: 1050-5261

File Segment: Medical & Pharmaceutical Biotechnology Abstracts; Nucleic Acids Abstracts: Immunology Abstracts

Abstract:

A synthetic 30-mer single-stranded oligodeoxyribonucleotide with a hexamer palindrome, AACGIT, induced IFN production and augmented NK activity in murine splenocytes. This effect does not appear to result from an antisense mechanism but rather is due to the palindrome. To clarify the required minimal size of the nucleotide, 10 kinds of 12- to 30-mer nucleotides were examined. Immunostimulatory activity of oligonucleotides 18 bases or more in length was observed and was proportional to.....16 bases or less in length were not active even if they possessed the palindromic sequence. These results indicate that the immunostimulatory activity of oligonucleotides with certain palindromic sequences requires an oligonucleotide at least 18 bases long.

Subj Catg: ...Antisense; 14250 Material Class:

4/3, K/27 (Item 6 from file: 24) Links Fulltext available through: STIC Full Text Retrieval Options CSA Life Sciences Abstracts (c) 2009 CSA. All rights reserved. 0001058036 IP Accession No: 2572893 Interaction of the v- and C-Mby proteins with regulatory sequences of the human

c-myc gene.

Zobel, A; Kalkbrenner, F; Guehmann, S; Nawrath, M; Vorbrueggen, G; Moelling, K Max-Planck-Inst. Mol. Genet., Abt. Schuster, Innestr. 73, D-1000 Berlin 33, FRG Oncogene, v 6, n 8, p 1397-1407, 1991 Addl. Source Info: Oncogene, vol. 6, no. 8, pp. 1397-1407, 1991 Publication Date: 1991

Document Type: Journal Article Record Type: Abstract Language: English Summary Language: English ISSN: 0950-9232 File Segment: Nucleic Acids Ab

File Segment: Nucleic Acids Abstracts; Human Genome Abstracts; Oncogenes & Growth Factors Abstracts

Abstract:

...different affinities whereby strong binding correlates better with conservation of the palindromic sequences, AACXGTT or AACGTT, than the previously described consensus sequence. Flanking AT-rich sequences further increase the binding affinity. The c-Myb-binding sites are...

Identifiers: genes; oncogenes; c-myc gene; binding; sites; regulatory; nucleotide sequence; man; non-cooperativity; Myb protein Subi Catg:

Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif

Author: Zhang Y; Shoda LKM; Brayton KA; Estes DM; Palmer GH; Brown WC (REPRINT)

STIC Full Text Retrieval Options

4/3,K/28 (Item 1 from file: 34) Links Fulltext available through: STIC F

4/3,K/30 (Item 1 from file: 71) Links

(c) 2009 Elsevier B.V. All rights reserved.

Yamamoto T.; Yamamoto S.; Kataoka T.; Tokunaga T.

Supplier Number: 1994168545

ELSEVIER BIOBASE

0000653430

(c) 2009 The Thomson Corp. All rights reserved. 10160766 Genuine Article#: 491GD No. References: 48

SciSearch(R) Cited Ref Sci

```
Corporate Source: Washington State Univ,Coll Vet Med, Dept Vet Microbiol & Pathol,Pullman/WA/99164 (REPRINT); Washington State Univ,Coll Vet Med, Dept Vet Microbiol & Pathol,Pullman/WA/99164; Univ Missouri,Coll Vet Med, Dept Pathobiol,Columbia/MMO/65211
Journal: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH , 2001 , V 21 , N10 ( OCT ) , P
871-881
ISSN: 1079-9907
                            Publication date: 20011000
Publisher: MARY ANN LIEBERT INC PUBL , 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
Language: English Document Type: ARTICLE ( ABSTRACT AVAILABLE )
Abstract: ...B cell proliferation at a lower concentration (10 mum) when compared
with CpG ODN containing AACGTT or GACGTT motifs active for murine leukocytes. Furthermore, ODN 2059 induced interleukin-6 (IL-6...
Identifiers-- ...SURFACE PROTEIN-2: NECROSIS-FACTOR-ALPHA: IFN-GAMMA PRODUCTION;
BACTERIAL-DNA; BABESIA-BOVIS; IN-VITRO; IMMUNOSTIMULATORY PROPERTIES;
IMMUNE-RESPONSES: TH1 IMMUNITY
 4/3,K/29 (Item 1 from file: 50) Links
     Fulltext available through: STIC Full Text Retrieval Options
CAB Abstracts
(c) 2009 CAB International. All rights reserved.
0008401615 CAB Accession Number: 20033043653
CpG oligodeoxynucleotides activate grass carp ( Ctenopharyngodon idellus [ idella ])
macrophages.
Meng Zhen; Shao JianZhong; Xiang LiXin
Author email address: lscshaoj@mail.hz.zj.cn
College of Life Sciences, Zhejiang University, Hangzhou 310012, China.
Developmental and Comparative Immunology vol. 27 (4): p.313-321
Publication Year: 2003
ISSN: 0145-305X
Digital Object Identifier: 10.1016/S0145-305X(02)00104-0
Publisher: Elsevier Science Inc. New York
Language: English Record Type: Abstract
                                                     New York , USA
Language: Engilsn Record Type: AUSTRACE
DOCUMENT Type: Journal article
... ODN-1826 (GACGTT) and -2006 (GTCGTT) for the mice and humans cells, the ODN-1670
(AACCGTT) used in Artlantic salmon, the ODN-D containing two repeats motif of those in
1670.... found and the ODN-D was not more efficient than 1670. It suggests that
the sequence which contains the unmethylated 'Cc' dinucleotides could make
contribute to this immunostimulatory effect. These findings indicate that CpG-ODNs
could be useful tools for understanding the important...
```

Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhancers interferon production and natural killer

Page 18

```
cpgaacgtt.txt
Corresp. Author/Affil: Yamamoto T., Dept. Bacterial and Blood Products, National Institute of Health, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208, Japan Journal: Microbiology and Immunology (MICROBIOL. IMMUNOL.), v38, n10, (831-836),
1994 , Japan
Publication Date: November 10, 1994 (19941110 )
Coden: MIIMD
ISSN: 0385-5600 eISSN: 1471-2970
Record Type: Abstract; New
Document Type: Article
Languages: English
                              Summary Languages: English
Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of
AACGTT to murine splenocytes enhancers interferon production and natural killer
activity
A synthetic 22-mer oligodeoxyribonucleotide having an AACGTT palindrome. AAC-22
induced interferon (IFN) production and augmented the natural killer (NK) activity
in...
 4/3,K/31 (Item 2 from file: 71) Links
ELSEVIER BIOBASE
(c) 2009 Elsevier B.V. All rights reserved.
0000606721 Supplier Number: 1994108402
0000606721
Myb proteins 'talking' to their DNA
Boulikas T.
Corresp. Author/Affil: Boulikas T., Inst. of Molecular Medical Sciences, 460 Page
Mill Road, Palo Alto, CA, 94306 , United States
Journal : International Journal of Oncology (INT. J. ONCOL. ) , v5, n1, (101-109) ,
1994 , Greece
Publication Date: June 21, 1994 (19940621 )
Coden: IJONE
ISSN: 1019-6439 eISSN: 1471-2970
Record Type: Abstract; New
Document Type: Review
Languages: English
                             Summary Languages: English
DNA sequence-specific proteins called transcription factors found in all
multicellular organisms control the expression of genes....mammals including
humans, plants, flies, Dictyostelium, and yeast. Myb proteins show a preference for
the AACGTT, AACGGTT and the T G AACAACTGAA motifs with AAC (or its complementary
GTT) as the ...
 4/3,K/32 (Item 1 from file: 72) Links
   Fulltext available through:
                                      STIC Full Text Retrieval Options
EMBASE
(c) 2009 Elsevier B.V. All rights reserved.
                EMBASE No: 2007117237
  Innovative restriction site created PCR-RFLP for detection of benzimidazole
resistance in Teladorsagia circumcincta
  Shayan P.; Eslami A.; Borji H.
  Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran,
Tehran, Iran, Islamic Republic of
Author email: pshayan@ut.ac.ir
Corresp. Author/Affil: Shayan P.: Department of Parasitology, Faculty of Veterinary
Medicine, University of Tehran, Tehran, Iran, Islamic Republic of
 Corresp. Author Email: pshayan@ut.ac.ir
  Parasitology Research ( Parasitol. Res. ) ( Germany ) April 1, 2007, 100/5
(1063-1068)
  CODEN: PARRE
                    ISSN: 0932-0113
Item Identifier (DOI): 10.1007/s00436-006-0357-y
```

Page 19

Document Type: Journal; Article Record Type: Abstract Language: English Summary language: English

Number of References: 27

...introduced modification in forward primer (UTVet MF-primer) leads to the creation of restriction site (AACGTT) for PSP1. Therefore, in the case of normal allele only, PSP1 can cut the corresponding...
Medical Descriptors:

animal experiment; article; controlled study; DNA flanking region; DNA isolation; female; gene amplification; gene sequence; heterozygote; homozygote; male; nonhuman; nucleotide sequence; priority journal; sheep Oriq. Descriptors:

4/3,K/33 (Item 2 from file: 72) Links Fulltext available through: STIC Full Text Retrieval Options EMBASE (c) 2009 Elsevier B.V. All rights reserved. 0079620924 EMBASE No: 2003328937

Enhanced cell-mediated IFN-gamma-secreting activity against the HIV-1 SUB IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering

Rodriguez E.G.; Vazquez D.M.; Herrera A.M.; Duarte C.A. Vaccine Division, Ctr. Genetic Eng./Biotech. of Havana, P.O. Box 6162, Havana

10600, Cuba Author email: ernesto.galban@cigb.edu.cu

Corresp. Author/Affil: Rodriguez E.G.: Vaccine Division, Ctr. Genetic Eng./Biotech. of Havana, P.O. Box 6162, Havana 10600, Cuba Corresp. Author Email: ernesto.galban@ciab.edu.cu

Biochemical and Biophysical Research Communications (Biochem. Biophys. Res. Commun.) (United States) September 5, 2003 , 308/4 (713-718) CODEN: BBRCA _ISSN: 0006-229

Item Identifier (DOI): 10.1016/S0006-291x(03)01462-1 Document Type: Journal ; Article Record Type: Abstract Language: English Summary language: English Number of References: 25

...beta globin-based termination/polyadenylation sequences, and 5, 10, and 20 copies of the Sprime-AACGIT-3prime CpG motif were inserted. Balb/c mice were immunized by intramuscular injection of 200mug...
Medical Descriptors:

...splicing; enzyme linked immunosorbent assay; enzyme linked immunospot assay; female; Fowlpox virus; gene insertion; gene sequence; genetic engineering; Human immunodeficiency virus 1; immunization; immunoassay; intron; mouse; nonhuman; polyadenylation; priority journal; promoter... orig. Descriptors:

4/3,K/34 (Item 3 from file: 72) Links Fulltext available through: STIC Full Text Retrieval Options EMBASE

(c) 2009 Elsevier B.V. All rights reserved. 0075876834 EMBASE_No: 1994295619

Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG

Yadmanoto S. National Institute of Health, Gakuen 4-7-1, Musashi-Murayama, Tokyo 208, Japan Corresp. Author/Affil: Yamamoto S.: National Institute of Health, Gakuen 4-7-1, Musashi-Murayama. Tokyo 208. Japan cpgaacgtt.txt October 17, 1994, 69/9 (571-574)

Kekkaku (KEKKAKU) (Japan) CODEN: KEKKA ISSN: 0022-9776

Document Type: Journal ; Article Record Type: Abstract

Language: Japanese Summary language: English

Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG

...size, and peaked at 45 nucleotides. We synthesized 13 kinds of 45-mer nucleotides with sequence present in the known cDNA encoding various BGG proteins. Six out of these oligonucleotides, which....cell activity of mouse spleen cells by coincubation in vitro. When a portion of the sequence of the inactive oligonucleotides was substituted with either palindromic sequence GAGGTC, AGGGTO OF AACGTT, the oligonucleotide acquired the ability to augment NK activity. In contrast, the oligonucleotide substituted with another palindromic sequence such as ACCGGT was without effect. Furthermore, exchange of two neighboring monoucleotides within, but not outside, the active palindromic sequence destroyed the ability of the oligonucleotide to augment NK activity. Taken together, these findings indicate that some, but not all, of....sequences also influenced the activity. Eighteen-mer to 30-mer oligonucleotides with 6-mer palindromic sequence as AACGTT showed the activity, while those less than 16-mer oligonucleotide sid not. A 30-mer oligonucleotide with a 10-mer palindromic oligognanylate sequences showed the strongest activity among....the incubation for 18-24 hr; lipofection was 3000-fold more efficient than the naked oligonucleotide with while an inactive 22-mer oligonucleotide, ACC-22, took little to induce IFN. The binding of SUP 32p-oligonucleotides to mouse....surface receptor to transfer the inducing signal into the cell. The reason why the active oligonucleotide possess activity is still obscure. A further study on the mode of action for IFN.

4/3,K/35 (Item 1 from file: 144) Links Pascal (c) 2009 INIST/CNRS. All rights reserved.

17106085 PASCAL No.: 05-0172909

DNA structure constraint is probably a fundamental factor inducing CpG deficiency in bacteria

YONG WANG; LEUNG Frederick C C
bepartment of Zoology, The University of Hong Kong, Pokfulam, Hong Kong
Journal: Bioinformatics: (Oxford. Print),
2004, 20 (18)
3336-3345

Language: English

Copyright (c) 2005 INIST-CNRS. All rights reserved.

Motivation: It has been speculated that CpG dinucleotide deficiency in genomes is a consequence of DNA methylation. However, this hypothesis does not adequately...

... the TTGGAA pattern, was under represented in low GC content bacterial genomes regardless of CpG dinucleotide level. This is in contrast to the AAGGTT pattern, indicating that the counterselection is context-dependent. Further study discovered nine underrepresented patterns that...

... proposed for the strong correlation between GC content and CpG deficiency. The result of random sequence simulation showed that the occurrences of these patterns were correlated with GC content, as well...

DNA sequence recognition of thiazole-containing cross-linked polyamides can be

Record type: MEDLINE; Completed
DNA sequence recognition of thiazole-containing cross-linked polyamides can be

The binding ability of cross-linked thiazolated polyamides (containing the base sequence-reading elements thiazole(Th)-pyrrole(Py)-pyr-role(Py) and

thiazole(Th)-imidazole(Im)-pyrrol.....concentration demonstrate that the dimers with a heptanediyl linker (C7 dimer) show a significantly higher sequence

Burckhardt G; Simon H; Birch-Hirschfeld E; Kittle L; Sharma S K; Lown J W; Zimmer C Institut fur Molekularbiologie, Friedrich-Schiller-Universitat (FSU) Jena, Winzerlaer Str. 10, D-07745 Jena, Germany. Journal of biomolecular structure & dynamics (United States) Jun 2002 ,

STIC Full Text Retrieval Options

19 (6)

4/3,K/36 (Item 1 from file: 154) Links

(c) format only 2009 Dialog. All rights reserved.

p1101-9 , ISSN: 0739-1102--Print Journal Code: 8404176

Document type: Journal Article; Research Support, Non-U.S. Gov't

Fulltext available through:

14798735 PMID: 12023812

Publishing Model Print

Languages: ENGLISH Main Citation Owner: NLM

MEDLINE(R)

favored.

favored.

```
with a heptanediy! Inker (C/ dimer) snow a significantly higher sequence specificity than their corresponding monomers. The dimer of Th-Py-Py primarily prefers binding to ... .. of Th-Im-Py to the dodecamer sequences containing a GC pair within the central sequence (e.g. AAGCIT). Surprisingly, the sequence binding ability is strongly influenced by the presence of a T-A step: e.g. ... .. of the cross-linked dimer to the minor groove is discussed in light of the sequence recognition of the TATA box binding protein.
Descriptors: ; AT Rich Sequence--physiology--PH; Animals; Binding Sites; Cattle;
DNA--genetics--GE; Ligands
Named Person:
 4/3,K/37 (Item 2 from file: 154) Links
    Fulltext available through:
                                                 STIC Full Text Retrieval Options
MEDLINE(R)
(c) format only 2009 Dialog. All rights reserved.
11280459 PMID: 7526022
[Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of
oligonucleotide fraction extracted from Mycobacterium bovis BCG]
National Institute of Health, Tokyo, Japan
Kekkaku - Tuberculosis ( JAPAN ) Sep 1994
                                                   Sep 1994 .
                                                                       69 (9) p571-4 . ISSN:
0022-9776--Print
                            Journal Code: 0422132
Publishing Model Print
Document type: English Abstract: Journal Article
Languages: JAPANESE
Main Citation Owner: NLM
Record type: MEDLINE: Completed
[Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG]
   .size, and peaked at 45 nucleotides. We synthesized 13 kinds of 45-mer nucleotides
with sequence present in the known cDNA encoding various BCG proteins. Six out of
```

these oligonucleotides, which.....cell activity of mouse spleen cells by Page 22

coincubation in vitro. When a portion of the sequence of the inactive oligonucleotides was substituted with either palindromic sequence of GACGTC, AGCGCT or AACGTT, the oligonucleotide acquired the ability to augment NK activity. In contrast, the oligonucleotides substituted with another palindromic sequence such as ACCGGT was without effect. Furthermore, exchange of two neighboring mononucleotides within, but not outside, the active palindromic sequence destroyed the ability of the oligonucleotide to augment NK activity.(AMSTRACT TRUNCATED AT 250 WORDS) (Descriptors; Animals; Awards and Prizes; Base Sequence; Interferons—biosynthesis—BI; killer Cells, Natural—immunology—IM; Mice; Molecular Sequence Data

4/3.K/38 (Ttem 3 from file: 154) Links Fulltext available through: STIC Full Text Retrieval Options MEDLINE(R) (c) format only 2009 Dialog. All rights reserved. 10339483 PMID: 1376349 Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. Yamamoto S; Yamamoto T; Kataoka T; Kuramoto E; Yano O; Tokunaga T Department of Cellular Immunology, National Institute of Health, Tokyo, Japan Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Jun 15 1992 148 (12) p4072-6 , ISSN: 0022-1767--Print Journal Code: 2985117R Publishing Model Print Jun 15 1992 . Document type: Journal Article; Research Support, Non-U.S. Gov't Languages: ENGLISH Main Citation Owner: NLM Record type: MEDLINE; Completed Thirty-mer single-stranded oligonucleotides, with a sequence chosen from the known CDNA encoding the 64-KDa protein named ag A or the.....cell activity of mouse spleen cells by coincubation in vitro. Three with the hexamer palindromic sequence as GACGTC were active, whereas two kinds of oligonucleotides with no palindrome were inactive. The.....least one of the different palindromic sequences showed no activity. When a portion of the sequence of the inactive oligonucleotides was substituted with either palindromic sequence of GACGTC, AGCGCT, or AACGTT, the oligonucleotide acquired the ability to augment NK activity. In contrast, the oligonucleotides substituted with another palindromic sequence such as ACCGGT was oligonic leotides substituted with another paindromic sequence such as Access, without effect. Furthermore, exchange of two neighboring mononucleotides within, but not outside, the active palindromic sequence destroyed the ability of the oligonic leotides to augment NK cell activity. Stimulation of spleen cells with the substituted oligonic leotide, A4a-AAC, induced production of significant amounts of IFN-alphA)beta and small amounts of IFN-alphA)beta and s cells by the oligonucleotide was ascribed to IFN-alpha/beta production. These results strongly suggest that the presence of the unique palindromic sequences, such as GACGTC, AGGCCT, and AACGTT, but not ACCGGT, is essential for the immunostimulatory activity of oligonucleotides. (Descriptors: | Animals; Base Sequence; Complement C1 Inactivator Proteins--genetics --GE; Cytotoxicity, Immunologic; Heat-Shock Proteins--genetics--GE; Mice; Mice, Imbred BALB, C; Molecular Sequence, Data; Mycobacterium boyls --genetics--GE;

4/3,K/39 (Item 1 from file: 370) Links Science (C) 1999 AAAS. All rights reserved. 00500536 (USE 9 FOR FULLIEXT) Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene

Named Person:

Immunization

Oligodeoxyribonucleotides--chemistry--CH; Structure-Activity Relationship

Sato, Yukio; Roman, Mark; Tighe, Helen; Lee, Delphine; Corr, Maripat; Nguyen,
Page 23

Minh-Duc; Silverman, Gregg J.; Lotz, Martin; Carson, Dennis A.; Raz, Eyal Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0663, USA.

Science Vol. 273 5273 pp. 352

Publication Date: 7-19-1996 (960719)
Document Type: Journal ISSN: 0036-8075 Publication Year: 1996

Language: English

Section Heading: Reports

word Count: 2127 (THIS IS THE FULLTEXT)

Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization

Abstract:

...immune responses to the encoded antigens. Instead, the immunogenicity of plasmid DNA (pDNA) requires short immunostimulatory DNA sequences (ISS) that contain a CpG dinucleotide in a particular base context. Human monocytes transfected with pDNA or double-stranded oligonucleotides containing...

Text:

- ...To test the hypothesis that the ampR sequence may up-regulate the immune response to (beta) -Gal in gene-vaccinated mice, we injected...
- ..Palindromic, single-stranded immunostimulatory DNA sequences (ISS) have been reported to induce production of IFN-a, IFN- (beta), and
- ...hexamers: 5 (prime) -GACGTC-3 (prime) , 5 (prime) -AG-CGCT-3 (prime) , and 5 (prime) -AACGTT-3 (prime) (B7) . Two repeats of 5 (prime) -AACGTT-3 (prime) were in the ampR gene, whereas no ISS were identified within the kanR gene (Fig. 1). To test the hypothesis that the 5 (prime) -AACGTT-3 (prime) ISS within the ampR gene facilitates the induction of CTL and T.inf...
- ...to (beta) -Gal, we subcloned either one or two repeats of the ISS 5 (prime) -AACGTT-3 (prime) to sites flanking the kank gene in the pKCB-Z vector. The new...
- .. The immunostimulatory effect of bacterial DNA was discovered by Tokunaga et al. (B8) . By synthesizing single-stranded...
- .activation (B10) . They found that cytosine methylation or the elimination of the CpG from the oligonucleotide abolished the lymphocyte stimulatory effect. The activation capability was attributed to a series of CpG...based vectors, we transfected in vitro fresh human monocytes with a panel of pDNAs, ISS oligonucleotide, and ISS-deficient oligonucleotide (B12) (B13) and them assessed by reverse transcription-polymerase chain reaction (RT-PCR) the expression...
- ...pKISS-1-CB, and double-stranded ISS digonucleotide, but not with pKCB or ISS-deficient oligonucleotide, enhanced within 3 hours mRNA amounts for all three cytokines (B12) (B13) . IFN-a plays...
- ..expression does not necessarily produce a stronger immune response. Both the localization and the precise sequence of the ISS within the plasmid backbone are also important for DNA vaccination. Thus, the...
- ...Fig. 1). In contrast, the addition of one or two repeats of the 5 Page 24

cpgaacgtt.txt
(prime) -AACGTT-3 (prime) sequence to the noncoding region
of the pkCB-Z backbone enhanced the immune response to (beta...

...of the 5 (prime) -GACGTC-3 (prime) , 5 (prime) -AGCGCT-3 (prime) , and 5 (prime) -AACGTT-3 (prime) palindromic ISS (B7) . The pACS and pACB vectors are pUC19-based plasmids (with the Pst I-Bam HI Sites of the aforementioned corresponding vectors. The putative immunostimulatory double-stranded oligonucleotide (sense, 5 (prime) -AATTGAACGTTCGC-3 (prime); antisense, 5 (prime) -AATTGGAACGTTC-3 (prime)) flanked by ECO RI-compatible overhangs was ligated into a unique Eco RI site of pACB, 3 (prime) to the BGHpA sequence. This resulted in the disruption of the Eco RI site and the creation of a new Pspl406I restriction site (AACGTT). The ISS-containing region was then subcloned (Bsp HI-Bam HI) into the pKCB and...

...2-CB and pKISS-2-CB-Z were constructed by ligation of the same ISS oligonucleotide into pKISS-1-CB and pKISS-1-CB-Z at a different Eco RI site...

References and Notes:

...of the annealed, blunt-end, double-stranded oligonucleotides used for transfection are as follows: ISS oligonucleotide, 5 (prime)
-TCATTGGAAAACGTTCTTCGGGCGC-3 (prime), from the ampR gene in the puc19 sequence (nucleotides 2288 to 2312); and ISS-deficient oligonucleotide, 5 (prime) -TCATTGGAAAAGGTTCTTGGGGGGG-3 (prime) . Bold nucleotides indicate the ISS...

4/3.K/40 (Item 1 from file: 393) Links Beilstein Database - Abstracts (c) 2008 Beilstein GmbH. All rights reserved. Beilstein Abstract Id: 6641612 Title: Influence of Backbone Chemistry on Immune Activation by Synthetic Oligonucleotides Document Type: Journal Record Type: Abstract Author: Pisetsky, David S.; Reich, Charles F. Citation: Biochem. Pharmacol. (1999) Series: 58-12, 1981 - 1988 CODEN: BCPCA6 Language: English Abstract Language: English Abstract: Depending on base sequence, DNA displays immunological activities relevant to the design of novel therapeutic agents. To determine the.....These compounds were 30 bases long and consisted of either a single base or an immunostimulatory sequence (AACGTT) flanked on 5' and 3' ends by 12 nucleotides of each base. Cell sequence (AACGT1) flanked on 5' and 3' ends by 12 nucleotides or each base. Ceri activation was....and cytokine production than the comparable phospholester compounds and had activity at lower concentrations. The sequence for optimal stimulation by phosphorothioates varied among responses, however. For example, whereas compounds containing an immunostimulatory sequence all induced similar levels of proliferation and CD69 expression, cytokine production was greatest with compounds....phosphodiesters and phosphorothioates, they failed to stimulate cytokine production. Together, these findings indicate that base sequence as well as backbone chemistry influence immune activation by synthetic oligonucleotides, with the effects varving... Abstract Language:

4/3,K/41 (Item 1 from file: 35) Links
Dissertation Abs Online
(c) 2009 ProQuest Info&Learning. All rights reserved.
01970603 ORDER NO: AADAA-Tc814652
Reactivity of human and porcine natural interferon-alpha producing cells to immunostimulatory DNA

```
Author: Magnusson, Mattias
Degree: Fil.dr.
Year: 2003
Corporate Source/Institution: Sveriges Lantbruksuniversitet (Sweden) ( 0697 )
Source: Volume 6501C of Dissertations Abstracts International.
PAGE 103 . 49 PAGES
ISBN: 91-576-6389-0
Publisher: Sveriges Lantbruksuniversitet, Box 7071, SE-750 07 Uppsala, Sweden Reactivity of human and porcine natural interferon-alpha producing cells to
immunostimulatory DNA
but pcDNA3 retained this ability after mutation of the CpG-motifs (5<super>&prime;</super>ACGIT 3<super>&prime;</super>) in the ampicillin resistance gene. Lipofection and presence of an unmethylated....of unmethylated CpG dinucleotides. This indicates that there are species differences in the recognition of
immunostimulatory DNA and that eukaryotic DNA sometimes can be interferogenic.
Certain CpG-containing ODNs with flanking....lipofectin, both as
phosphorothioate/phosphodiester chimeric ODNs or as phosphodiester ODNs. Addition of
poly-G, sequence to the phosphodiester ODN H clearly enhanced its activity, but did
not replace the need.....the only cells among human or porcine PBMC that produced IFN-8alpha; in response to immunostimulatory DNA.

The human NIPC/PDC also produce IFN-8alpha; in response to apoptotic cells in...

...bind, Fcγ had a general inhibitory effect on IFN-8alpha; production
induced by immunostimulatory DNA or herpes simplex virus.
     Elucidation of the mechanisms whereby NIPC/PDC are activated may...
 4/3.K/42 (Item 2 from file: 35) Links
Dissertation Abs Online
(c) 2009 ProQuest Info&Learning. All rights reserved.
01940291 ORDER NO: AADAA-I3086326
Effects of immunostimulatory DNA sequences on bovine immune responses
Author: Zhang, Yan
Degree: Ph.D.
Year: 2002
Corporate Source/Institution: Washington State University ( 0251 )
Source: Volume 6403B of Dissertations Abstracts International.
PAGE 1125 . 73 PAGES
Effects of immunostimulatory DNA sequences on bovine immune responses
      ...cell proliferation at a lower concentration (10 &mu:M) when compared with CpG
ODN containing AACGTT or GACGTT motifs active for murine leukocytes. Furthermore,
ODN 2059 induced IL-6 production by...
 4/3,K/43 (Item 1 from file: 44) Links
Aquatic Science & Fisheries Abstracts (c) 2009 CSA. All rights reserved.
0000866811
                   IP Accession No: 5341511
CpG oligodeoxynucleotides enhance the non-specific immune responses on carp,
Cyprinus carpio
Book Title: 6th Asian Fisheries Forum Book of Abstracts
Malina, AC; Tassakka, AR; Sakai, Masahiro Faculty of Agriculture, Miyazaki University, Gakuen Kibanadai Nishi 1-1, Miyazaki 889-2192, Miyazaki, Japan,
[mailto:m.sakai@cc.miyazaki-u.ac.jp]
 , p p. 217 , 2001
Publication Date: 2001
Publisher: Asian Fisheries Society, Unit A. Mayaman Townhomes 25 Mayaman Streeet UP
Village, Quezon City Philippines
                                                    Page 26
```

Conference:

6. Asian Fisheries Forum, Kaohsiung (Taiwan), 25-30 Nov 2001

Document Type: Book Monograph; Conference Record Type: Abstract

Language: English ASFA NO: CS0208566

File Segment: ASFA Marine Biotechnology Abstracts: ASFA 1: Biological Sciences & Living Resources: ASFA Aguaculture Abstracts

Abstract:

...ability to enhance the non-specific immune response in carp. The oligodeoxynucleotides containing the fish-immunostimulatory motif 5'-AACGTT-3' with the following sequences; ODN A = GCT AGA CGT TAA CGT T and ODN...

4/3,K/44 (Item 1 from file: 135) Links NewsRx Weekly Reports (c) 2009 NewsRx. All rights reserved.

0000878440 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Findings from University of Southampton advance knowledge in DNA research

Life Science Weekly, September 2, 2008, p.2811

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count: 490

8 SEP 2 - (& NewsRx.net) -- Research findings, 'The effects of

local DNA sequence on the interaction of ligands with their preferred binding sites, are discussed in a new...

Biochimie "We have examined the effects of local DNA sequence on the interaction of distamycin, Hoechst 33258, echinomycin, actinomycin and mithramycin with their preferred binding sites using a series of DNA fragments that contain every symmetrical hexanucleotide sequence. In several instances we find that the affinity for the ligands' preferred binding sites is...

...yet shows no binding to TTCGAA, TGCGCA and AGCGCT, while the best binding is to AACGTT. The tetranucleotides CGG and ACGT produce consistently good binding sites, irrespective of the surrounding sequences

...to all the potential symmetrical hexanucleotides and provide insights into the effects of local DNA sequence on ligand-DNA interactions. Hampshire and colleagues published their study in Biochimie (The effects of local DNA sequence on the interaction of ligands with their preferred binding sites. Biochimie , 2008;90(7):988...

.Medicales Elsevier, 23 Rue Linois, 75724 Paris, France. Keywords: United Kingdom, Southampton, DNA Research, DNA Sequence Proteomics,
Deoxyribonucleic Acid. This article was prepared by Life Science Weekly editors from staff and...

DESCRIPTORS:

United Kingdom; Southampton; DNA Research; DNA Sequence Proteomics; Deoxyribonucleic AcidAll

News: Professional News

4/3.K/45 (Item 1 from file: 185) Links Fulltext available through: STIC Full Text Retrieval Options

Zoological Record Online(R)

(c) 2009 The Thomson Corp. All rights reserved.

09019699 BIOSIS No. 14411065460
The expression profile of TLR9 mRNA and CpG ODNs immunostimulatory actions in the

teleost gilthead seabream points to a major role of lymphocytes.

Authors: Cuesta, A. (a); Esteban, M.A.; Meseguer, J. Authors Address: (a) Univ Murcia, Fac Biol, E-30100 Murcia; Spain

Source: CMLS Cellular and Molecular Life Sciences 65(13), July 2008: 2091-2104. [Print]

Document Type: Article

ISSN: 1420-682x Languages: English Record Type: Abstract

The expression profile of TLR9 mRNA and CpG ODNs immunostimulatory actions in the teleost gilthead seabream points to a major role of lymphocytes.

Abstract: ...cell-source To conclude, ODNs containing GACGTT, GTCGTT (optimal for mouse and human, respectively) or AACGTT motifs are the most potent inducers of seabream immunity, whilst the involvement of TLR9 is... Descriptors:

...Immunostimulatory potential of oligodeoxynucleotides

4/3,K/46 (Item 1 from file: 357) Links

Derwent Biotech Res. (c) 2009 Thomson Reuters. All rights reserved. 0388765 DBA Accession No.: 2006-02261 PATENT

New immunostimulatory oligonucleotide of at least 8 nucleotides in length, useful in preparing a vaccine ágainst infections caused by bacteria, parasites or virus, e.g. Hemophilus influenza or Mycobacterium tuberculosis immunostimulatory oligonucleotide for nucleic acid vaccine and infectious disease therapy and gene therapy

Author: KRIEG A M; KLINE J; KLINMAN D; STEINBERG A D Patent Assignee: ÚNIV IOWA RES FOUND; COLEY PHARM GROUP INC; US DEPT HEALTH and HUMAN SERVICES 2005 Patent Number: US 20050277609 Patent Date: 20051215 WPI Accession No.: 2006-028460

(200603)

Priority Application Number: US 31460 Application Date: 20050107
National Application Number: US 31460 Application Date: 20050107

Language: English New immunostimulatory oligonucleotide of at least 8 nucleotides in length, useful in preparing a vaccine against infections caused by bacteria, parasites or virus, e.g. Hemophilus influenza or Mycobacterium tuberculosis immunostimulatory oligonucleotide for nucleic acid vaccine and infectious disease therapy and gene therapy

Abstract: DERWENT ABSTRACT: NOVELTY - A new immunostimulatory oligonucleotide of at least 8 nucleotides in length comprises a sequence having 6 base pairs. DETAILED DESCRIPTION - A new immunostimulatory oligonucleotide of at least 8 nucleotides in length comprises a sequence consisting of AACGTC or GGCGTF. INDEPENDENT CLAIMS are

also included for: (1) an immunostimulatory composition comprising the immunostimulatory oligonucleotide and an antigen, adjuvant or immunotherapy; (2) Page 28

modulating an immune response: (3) preventing an infectious disease; and (4) screening for human immunostimulatory activity of oligonucleotides. BIOTECHNOLOGY -Preferred Oligonucleotide: The immunostimulatory oligonucleotide includes more than one CpG motif. The immunostimulatory oligonucleotide of at least 8 nucleotides in length is represented by the formula (I) or (II....is TpT, CpT or GpT. X1, X2, X3 and X4 are nucleotides. Preferred Composition: The immunostimulatory composition comprises an immunostimulatory nucleic acid and an antigen. The immunostimulatory nucleic acid comprises 5'-cytosine, guanine-3'. The immunostimulatory nucleic acid and the antigen are proximately associated at a distance effective to enhance an amu the antigen are proximately associated at a distance effective to enhance an immune response. The immunostimulatory nucleic acid comprises a palindromic region, comprising the sequence 5'-cytosine, guanine, 9': The immunostimulatory nucleic acid comprises 5'-purine, purine, cytosine, guanine, pyrimidine, pyrimidiary. The immunostimulatory nucleic acid comprises a sequence consisting of AAGGTT, AGGGTT, GAGGTT, GAGGT associated such that the immunostimulatory nucleic acid and the antigen are co-delivered to an immune target. The immune target... ...cell. The antigen-presenting cell is a dendritic or macrophage cell, or a lymphocyte. The immunostimulatory composition further comprises an adjuvant. Preferred Method: Modulating an immune response in a subject comprises administering the immunostimulatory oligonucleotide or immunostimulatory composition to a subject in an amount sufficient to modulate the immune response. The method... ...papiljomavirus or human immunodeficiency virus, Preventing an infectious disease in a subject comprises administering the immunostimulatory composition. The infectious disease is due to a viral, bacterial or parasitic infection. The virus is Hemophilus influenza or Mycobacterium tuberculosis. Screening for human immunostimulatory activity of oligonucleotides comprises: (a) providing macrophage cells and an oligonucleotide to be tested; (b) incubating the cells and oligonucleotide of step (a) for an appropriate length of time; and (c) determining the relative amount.....ACTIVITY - Antibacterial, Virucide; Antiparasitic No biological data is given MECHANISM OF ACTION - Vaccine. USE - The immunostimulatory ojigonucleotide is useful in preparing a composition for preventing an infectious disease caused by bacteria, parasites... E.C. Numbers:

Descriptors: immunostimulatory oligonucleotide, antigen, adjuvant, immunotherapy immune response modulation, húman immunostimulatory act. screening, appl. nucleic acid vaccine, parasite, virus, Hemophilus influenza, Mycobacterium tuberculosis infectious disease therapy, prevention, gene therapy animal mammal bacterium DNA sequence (25, 04)

4/3.K/47 (Item 2 from file: 357) Links Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved. 0374956 DBA Accession No.: 2005-20662 PATENT

Treating viral infection in a subject comprises administering to a subject an immunostimulatory nucleic acid molecule comprising an unmethylated CpG dinucleotide, in an amount effective to treat or ameliorate a viral infection method of gene therapy of a virus infection involving the use of an unmethylated CpG dinucleotide encoded by a plasmid immunostimulant

Author: KRIEG A M: KLINMAN D: STEINBERG A D Patent Assignee: UNIV IOWA RES FOUND: US DEPT HEALTH and HUMAN SERVICES

Patent Number: US 20050148537 Patent Date: 20050707 WPI Accession No.: 2005-478101 (200548)

Priority Application Number: US 987146 Application Date: 20041112
National Application Number: US 987146 Application Date: 20041112

Language: English

Treating viral infection in a subject comprises administering to a subject an immunostimulatory nucleic acid molecule comprising an unmethylated CpG dinucleotide, in an amount effective to treat or ameliorate a viral infection method of gene therapy of a virus infection involving the use of an unmethylated CpG dinucleotide Page 29

encoded by a plasmid immunostimulant Abstract: DERWENT ABSTRACT: NOVELTY - Treating viral infection in a subject comprises administering to a subject an immunostimulatory nucleic acid molecule comprising an unmethylated Cpg dinucleatiment, in an amount effective to treat or ameliorate a viral infection, thus treating the infection in the subject. WIDER DISCLOSURE - Also disclosed includes an immunostimulatory nucleic acid molecule. BIOTECHNOLOGY - Preferred Method: In treating viral infection in a subject, the immunostimulatory nucleic acid molecule is an immunostimulatory oligodeoxyribonucleotide, purified bacterial DNA, a plasmid DNA including sufficient immunostimulatory motifs to be immunostimulatory, or a plasmid DNA which after being administered to the subject is degraded into oligonucleotides. The immunostimulatory administered to the subject is degraded into oligonucleotides. The immunostimulatory nucleic acid molecule comprises a CDG motific composed of an unmethylated by two 5' purines and two 3' pyrimidines. The immunostimulatory nucleic acid molecule comprises a CDG motif in which the CDG is Flanked by a 5' GDT inducleotide and two 3' pyrimidines. The immunostimulatory nucleic acid molecule is 8-100 nucleotides long and comprises a CDG motif represented by....as GDT, GDG, GDA, TDT, CDT and GDT The immunomodulatory nucleic acid molecule comprises a sequence selected from: AAGCCCT, AACGCCT, AACGCCT GACGCC; GACGCT; GACGTĆ; GACGTĆ; GGCGCĆ; GGCGCĆ; GGCGTĆ; GGCGTĆ; ATCGCĆ; ATCGCĆ; ATCGTC.. E.C. Numbers: Descriptors: plasmid, unmethylated CpG dinucleotide, immunostimulant, appl., virus infection gene therapy virucide DNA sequence (24, 33) 4/3.K/48 (Item 3 from file: 357) Links Derwent Biotech Res. (c) 2009 Thomson Reuters. All rights reserved. 0359372 DBA Accession No.: 2005-05076 PATENT Use of an immunostimulatory oligonucleotide for boosting an immune response of a subject, or for stimulating an immune response in a subject, where increases in IFN-gamma and IL-12 expression are indicators of the immune response immunostimulatory oligonucleotide and vaccine for use in disease therapy and gene therapy Author: KRIEG A M; KLINMAN D; STEINBERG A D Patent Assignee: UNIV IOWA RES FOUND; COLEY PHARM GROUP INC; US DEPT COMMERCE and NAT INST STANDARDS 2005 Patent Number: US 20050004062 Patent Date: 20050106 WPI Accession No.: 2005-065257 (200507) Priority Application Number: US 847650 Application Date: 20040517 National Application Number: US 847650 Application Date: 20040517 Language: English Use of an immunostimulatory oligonucleotide for boosting an immune response of a subject, or for stimulating an immune response in.....where increases in IFN-gamma and IL-12 expression are indicators of the immune response immunostimulatory oligonucleotide and vaccine for use in disease therapy and gene therapy Abstract: DERWENT ABSTRACT: NOVELTY - Using an immunostimulatory oligonucleotide for boosting an immune response of a SUD-jet or for stimulating an immune response in....
...Method: Boosting an immune response of a subject comprises administering to the subject and isolated immunostimulatory oligonucleotide comprising the hexameric sequence (I) X1X2CGX3X4, where C and G are unmethylated and X1-X4 are nucleotides, and the immunostimulatory oligonucleotide is 6-100 bases in length, and an increase and the immunostimulatory oligonucleotide is 0-100 bases in length, and an increase in activation of the subject's....antigen receptors specific for the bacterial antigens. The immunostimulatory oligonucleotide is 8-100, preferably 8-40 bases in length. It is administered in conjunction with.....12 expression are indicators of the immune response comprises administering to the subject an isolated immunostimulatory oligonucleotide comprising (1), in an amount where IFN-gamma and IL-12 expression is increased. The Comprising (1), in an amount where the same and the sequence consisting of 5 purine-purine-Co-pyrimidine-pyrimidine-3'. It also comprises AGGIT, GACGTC, or GACGIT in the infection is a viral infection. Boosting the immune responsiveness of. a... ...a sensitizing antigen without immunization of the subject by the sensitizing Page 30

antigen comprises administering an immunostimulatory oligonucleotide to the subject. where an increase in the magnitude of the subject's immune response... ... response of a subject to a sensitizing antigen toward a ThI phenotype comprises administering an immunostimulatory oligonucleotide to the subject, where detection of a ThI type immune response by the subject indicates.....The desired result is measured by detecting in a sample containing lymphocytes obtained from the immunostimulatory oligonucleotide treated subject higher levels of II-12 and/or IFM-gamma in the immunostimulatory oligonucleotide treated subject as compared to an antigen-challenged control. ACTIVITY - Antiinflammatory; dermatological; Immunosuppressive; Antibacterial; Virucide. No biological data given. MECHANISM OF ACTION - None given. USE - The immunostimulatory oligonucleotide is useful for boosting an immune response of a subject or stimulating an immune response... E.C. Numbers:
Descriptors: immunostimulatory oligonucleotide, interferon-gamma, interleukin-12

expression increasing, vaccine, appl. immune response boosting, stimulation, systemic lupus erythematosus...

4/3,K/49 (Item 4 from file: 357) Links Derwent Biotech Res. (c) 2009 Thomson Reuters. All rights reserved. 0359371 DBA Accession No.: 2005-05075 PATENT Use of an immunostimulatory oligonucleotide for preventing or suppressing antigen-stimulated, eosinophilic inflammation in an antigen-exposed subject, or shifting the immune response of a subject to an antigen toward a Thi immune response oligonucleotide and vaccine for use in disease therapy and gene therapy Author: KRIEG A M; KLINE J; KLINMAN D; STEINBERG A D Patent Assignee: UNIV IOWA RES FOUND; COLEY PHARM GROUP INC; US SEC OF ARMY 2005 Patent Number: US 20050004061 Patent Date: 20050106 WPI Accession No.: 2005-065256 (200507) Priority Application Number: US 847642 Application Date: 20040517 National Application Number: US 847642 Application Date: 20040517 Language: English Use of an immunostimulatory oligonucleotide for preventing or suppressing antigen-stimulated, eosinophilič inflammation in an antigen-exposed subject, or shifting the immune response of a subject to an antigen toward a Th1 immune response oligonucleotide and vaccine for use in disease therapy and gene therapy oligonucleotide and vaccine for use in disease therapy and gene therapy Abstract: DERWENT ABSTRACT: NOVELTY - Using an immunostimulatory oligonucleotide for preventing or suppressing antigen-stimulated, eosinophilic inflammation in an antigen-exposed subject, boosting an. . . . stimulated, eosinophilic inflammation in an antigen-exposed subject comprises administering to the subject an isolated immunostimulatory oligonucleotide comprising the sequence (I): XIX2CGX3X4, where C and G are unmethylated and XI-X4 are nucleotides, and the immunostimulatory oligonucleotide is 6-100 bases in length, in an amount to suppress a Th2 immune response, where eosinophilic inflammation is prevented or suppressed. The Boosting an immune response of a subject comprises administering to the subject an solated immunostimulatory oligonucleotide comprising (I), where an increase in activation of the subject's lymphocytes or NK cells....antigen receptors specific for the bacterial antigens, The immune system deficiency is also cancer. The immunostimulatory oligonucleotide is administered in conjunction with a vaccine. It may not also be administered in conjunction....to an antigen toward a Th1 immune response_comprises administering to the subject an isolated immunostimulatory oligonucleotide comprising (I), where detection of a Th1 type immune response by the subject indicates that.....The desired result is measured by detecting in a sample containing lymphocyte obtained from the immunostimulatory oligonucleotide treated Page 31

subject, a lower level of IL-4 in the immunostimulatory oligonucleotide treated subject as compared to an antigen-challenged control, or a higher level of IL-12-and/or IFN-gamma in the immunostimulatory oligonucleotide treated subject as compared to an antigen-challenged control. Prevention or suppression of eosinophilic infilammation.....by detecting lower levels of eosinophils in an inflammatory infiltrate in the lung in an immunostimulatory oligonucleotide treated subject as compared to an antigen-challenged control. Preventing or reducing antigen-stimulated, granulocyte-mediated inflammation in a tissue of an antigen-sensitized subject comprises administering an isolated immunostimulatory oligonucleotide to the subject, where a reduction in, or the absence of, a Th2 type immune.....The desired result is measured by detecting in a sample containing Immunication of the immunostimulatory ofigonucleotide treated subject, a lower level of IL-4 in the immunostimulatory ofigonucleotide treated subject as compared to an antigen-challenged control, or a higher level of IL-12 and/or IFN-gamma in the immunostimulatory ofigonucleotide treated subject ms compared to an antigen-challenged control, Boosting the immune responsiveness of a... ...sensitizing antigen without immunization of the subject by the sensitizing antigen comprises administering an isolated immunostimulatory oligonucleotide to the subject, where an increase in the magnitude of the subject's immune response... ...of a subject to a sensitizing antigen toward a Th1 phenotype comprises administering an isolated immunostimulatory oligonucleotide to the subject, where detection of a Th1 type immune response by the subject indicates.....The desired result is measured by detecting in a sample containing lymphocytes obtained from the immunostimulatory oligonucleotide treated subject, a lower level of IL-4 in the immunostimulatory oligonucleotide treated subject as compared to an antigen-challenged control, or a higher level of IL-12 and/or IFN-gamma in the immunostimulatory oligonucleotide treated subject as compared to an antigen-challenged control. Reduction or suppression of inflammation is.. ". Dermatological; Ophthalmological; Antiparasitic; Virucide, No biological data given. MECHANISM OF ACTION - None given. USE - The immunostimulatory oligonucleotide is useful for preventing or suppressing antigen-stimulated, eosinophilis inflammation in an antigen-exposed subject... E.C. Numbers:

Descriptors: immunostimulatory oligonucleotide, Th1 immune response, vaccine, appl. antigen-stimulated, eosinophilic inflammation suppression, immune response shifting, immune responsive...

4/3,K/50 (Item 5 from file: 357) Links Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved. 0356187 DBA Accession No.: 2005-01891 PATENT

Effecting an improved response to a vaccine to treat or prevent an immune system deficiency (e.g. cancer) comprises administering an amount of an immunostimulatory oligonucleotide before administering the vaccine to the subject an immunostimulant for use as an adjuvant for a vaccine against cancer, infection or atopic disease

Author: KRIEG A M; KLINE J; KLINMAN D; STEINBERG A D Patent Assignee: UNIV IOWA RES FOUND; COLEY PHARM GROUP INC; US SEC OF ARMY 2004 Patent Number: US 20040229835 Patent Date: 20041118 WPI Accession No.: 2004-813305 (200480)

Priority Application Number: US 877407 Application Date: 20040624 National Application Number: US 877407 Application Date: 20040624

Language: English

...or prevent an immune system deficiency (e.g. cancer) comprises administering an amount of an immunostimulatory oligonucleotide before administering the vaccine to the subject an immunostimulant for use as an adjuvant for... Abstract: ...an improved response to a vaccine comprises administering to a subject an amount of an immunost imulatory ofligonucleotide before administering a vaccine the subject to boost the subject's immune system and effect an improved response to the vaccine. DETAILED DESCRIPTION - The immunostimulatory oligonucleotide is 8-100 nucleotides long and comprises a mitogenic CpG motif 5' x1x2CGX3X4 3', where...

... The infectious organism is selected from viruses, infectious bacteria,

mycobacteria, infectious fungi, and parasites. The immunostimulatory oligonucleotide is a DNA or RNA oligonucleotidé comprising an unmethylated cytosine-quanine (CpG) dinucleotide. The CDG motif is AACGTT, AGCGTT, GACGTT, GGCGTT, GTCGTT, GTCGCT, GGCGCT, GACGCT, or AACGCT. The X1X2 are nucleotides selected from.......GpA and ApA, and the X3X4 are nucleotides selected from TpT, CpT, and GpT. The immunostimulatory oligonucleotide comprises a phosphorothioate or phosphorodithioate backbone modification. ACTIVITY - Immunostimulant; Cytostatic; Virucide; Fungicide; Antibacterial; Antiparasitic; Antiallergic.....bacterial or parasitic infection), an atopic disease (including atopic dermatitis) or an allergy. ADMINISTRATION - The immunostimulatory oligonucleotide is administered via a systemic route, such as subcutaneous or intravenous (claimed). No dosage given... E.C. Numbers:

Descriptors: ...infection, atopic dermatitis, allergy, prevention, gene therapy tumor cytostatic virucide fungicide antibacterial antiallergic dermatological DNA sequence (24, 03)

4/3.K/51 (Item 6 from file: 357) Links Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0339787 DBA Accession No.: 2004-12079 PATENT New polypeptide, useful for identifying key amino acids in a TLR9 of a first species which confer specificity for Cpc DNA optimized for TLR9 of the first species recombinant protein production via plasmid expression in host cell for use in amino acid identification

Author: LIPFORD G B; MOOKHERJEE N; BABIUK L; BROWNLIE R; GRIEBEL P; MUTWIRI G; Patent Assignee: COLEY PHARM GMBH; UNIV SASKATCHEWAN; QIAGEN GMBH Patent Number: WO 200426888 Patent Date: 20040401 WPI Accession No.: 2004-295374 (200427) Priority Application Number: US 412479 Application Date: 20020919
National Application Number: WO 2003US29577 Application Date: 20030919 Language: English Abstract: DERWENT ABSTRACT: NOVELTY - A new isolated polypeptide comprises a sequence having 821, 819, 820, 818, 1032, 1030, 1029, 1031 or 1029 amino acids. DETAILED DESCRIPTION.....CLAIMS are also included for the following: (1) an isolated nucleic acid molecule comprising a sequence encoding the polypeptide; (2) a vector comprising the nucleic acid; (3) a cell comprising the polypeptide; (2) linked to a promoter sensitive to NF-KB. The candidate TLR9 ligand is an immunostimulatory nucleic acid. The immunostimulatory nucleic acid is CpG DNA. The screening method to identify species-specific CpG-motif preference....isolated polypeptide comprises: (1) contacting an isolated polypeptide with a CpG DNA polyperide Comprises. (1) Contacting an isolated polyperide with a CpG bNA comprising a hexanier sequence consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GACGTT, GACGTT E.C. Numbers:

Descriptors: ...gene transfer expression in host cell, antibody, appl. amino acid identification, CpG DNA optimization DNA sequence protein sequence (23, 25)

```
4/3,K/52 (Item 7 from file: 357) Links
```

Derwent Biotech Res.

Author: CURTISS R; KONG W

⁽c) 2009 Thomson Reuters. All rights reserved. 0337898 DBA Accession No.: 2004-10190 PATENT

New host-vector system comprising a host chromosome, and a vector, useful as a vaccine for immunizing a poultry, preferably chicken, against coccidiosis for use vaccine and fowl immunization

Patent Assignee: UNIV WASHINGTON Patent Number: WO 200420643 Patent Date: 20040311 WPI Accession No.: 2004-239203 (200422)

Priority Application Number: US 407522 Application Date: 20020901 National Application Number: WO 2003US26883 Application Date: 20030829

Language: English

Abstract: ... DESCRIPTION - The host-vector system comprises: (a) a host chromosome comprising: (i) an activatible control sequence that is activatible by an inducer; (ii) a sequence that encodes a repressor, where the sequence is operably-linked to the activatible control sequence; and (iii) at least one essential gene that encodes a polypeptide that is necessary for....is inactivated; and (b) a vector comprising: (i) a eukaryotic expression cassette comprising eukaryotic promoter comprising: (i) a dukaryotic expression cassette Comprising dukaryotic promoter sequence; site for insertion of a gene encoding a desired gene product; and a polyadenylation sequence; (ii) a prokaryotic activator-promoter sequence; (iii) a least one origin of replication (ori); (iv) a regulatable prokaryotic promoter, which is....rigid layer of a cell wall of a prokaryote; (vi) at least one transcription terminator sequence; and (vii) at least one tops sequence motif that enhances immunogenicity. INDEPENDENT CLAIMS are included for the following: (1) a microorganism comprising.....from Eimeria, HBV, or Streptococcus pneumoniae. The eukaryotic promoter is CMV. The prokaryotic activator-promoter sequence is araC Pbad. The ori is puc, pBR, p15A, pSC101, or pBAC. The regulatable control sequence is P22 Pr or Ptrc. The repressor is C2, Lac I, or both. The essential....has mutation that changes an ATG start codon to GTG or TTG. The terminator sequence is rrFG. This system comprises at least three terminator sequences, or at least two essential genes. The CpG sequence motif is GTCGTT, GACGTT, GACGTC, AACGTT or AGCGCT. The inducer is arabinose. The first and second inducers are arabinose. The host... F.C. Numbers:

4/3,K/53 (Item 8 from file: 357) Links Derwent Biotech Res. (c) 2009 Thomson Reuters. All rights reserved. 0332441 DBA Accession No.: 2004-04733 PATENT

Detecting an epigenetic abnormality associated with a disease by identifying, within a eukaryotic genome, a locus having a hypomethylated sequence specific for the disease and an endogenous multi-copy DNA element for use in Huntington chorea, schizophrenia and bipolar disorder therapy

Author: PETRONIS A

Patent Assignee: CENT ADDICTION and MENTAL HEALTH 2003
Patent Number: WO 2003104487 Patent Date: 20031218 WPI Accession No.: 2004-062375

(200406)

Priority Application Number: US 386818 Application Date: 20020606 National Application Number: WO 2003CA820 Application Date: 20030606

Language: English ...associated with a disease by identifying, within a eukaryotic genome, a locus having a hypomethylated sequence specific for the disease and an endogenous multi-copy DNA element for use in Huntington...

Abstract: ...associated with a disease Comprises identifying, within a eukaryotic genome, a locus having a hypomethylated sequence specific for the disease and an endogenous multi-copy DNA element. DETAILED DESCRIPTION _ INDEPENDENT CLAIMS... ...chromosomal region associated with a disease state; (2) a method of identifying a DNA coding sequence having an epigenetically altered expression pattern that contributes to a disease in an organism; (3.....a disease, the step of identifying comprises separate steps of identifying the disease-specific hypomethylated sequence and identifying the endogenous multi-copy DNA element. The steps may be performed in any order. The disease-specific hypomethylated sequence and the endogenous

multi-copy DNA element are within 10 kilobases of separation. The endogenous... ...comprises identifying a locus, within DNA obtained from the diseased sample, that has a DNA sequence that is hypomethylated and an endogenous multi-copy DNA element, where the DNA sequence is methylated in a non-disease sample and where the chromosomal region consists of from.....10 DNA coding sequences that are proximal to the identified locus. Identifying a DNA coding sequence having an epigenetically

altered expression pattern that contributes to a disease in an organism comprises identifying a locus, within DNA obtained from the diseased sample, that has a DNA sequence that is hypomethylated and an endogenous multi-copy DNA element, the DNA sequence thing is sphowledged in a non-disease sample and comparing expression patterns of the DNA coding sequence that comprises, or that is located proximal to, the identified locus within the diseased sample and the non-diseased sample to identify the DNA coding sequence having an epigenetically altered expression pattern. The disease comprises Huntington's disease, schizophrenia or bipolar disorder Diagnosing an epigenetic abnormality correlated with a disease comprises identifying a DNA sequence that is hypomethylated within a locus that has an endogenous a DNA sequence that is hypomethylated within a locus that has an endogenous multi-copy DNA element and is obtained from a diseased sample, the DNA sequence being methylated in a non-disease sample. Detecting an epigenetic abnormality associated with a non....produce a PCR product; (e) cloning of the PCR product into a sequencing vector; (f) sequence determination of the PCR product to obtain a sequence of the PCR product; and (g) comparing the sequence against a genomic database to assign a locus for the epigenetic abnormality associated with a... ...DNA element is a multicopy DNA element. The multi-copy DNA element comprises ...DNA element 15 a multicopy DNA element. The multi-copy DNA element comprises endogenous retroviral sequence, LINE, SINE, Ll or Alu. The methylation-sensitive restriction enzyme comprises AatII (GACGTC); Bsh1236I (CGGC... .Kpn2I (TCCGGC); Mul (GACGCT); NotI (GCGCC); Nsb1 (TGCGCA); PauI (GCGCC); Pd1 (GCGGC); Pf123II (CGTACG); Psp1406I (AACGTT); PvuI (CGATCG); SalI (GTCGAC); SmaI (CCCGGC); SmuI (CCCGC); Tail (ACGT) or TauI (GCSGC). Identifying a.....produce a PCR product; (e) cloning of the PCR product into a sequencing vector; (f) sequence determination of the PCR product to obtain a sequence of the PCR product; (g) comparing the sequence against a genomic database to assign a locus for the epigenetic abnormality associated with a... ...with an epigenetic abnormality comprises identifying, within a eukaryotic genome, a locus having a hypomethylated sequence specific for the disease and an endogenous multi-copy DNA element. Diagnosing a disease correlated with an epigenetic abnormality comprises identifying a DNA sequence that is hypomethylated within a locus that has an endogenous multi-copy lnA element and is obtained from a diseased sample, the DNA sequence being methylated in a non-disease sample useful for detecting an... E.C. Numbers:

Descriptors: DNA sequence, polymerase chain reaction, vector-mediated gene transfer, expression in host cell, appl. Huntington chorea, schizophrenia ...

```
Derwent Biotech Res.
(C) 2009 Thomson Reuters. All rights reserved.
0330149 DBA Accession No.: 2004-02441 PATENT
New nucleic acids, useful for inhibiting the synthesis of a target protein in a
eukaryotic cell, or for treating various diseases by inhibiting the expression of abnormal or mutated proteins, e.g. leukemia, viral or bacterial infection target protein inhibition and viru vector expression in host cell for use in disease gene
therapy
```

4/3,K/54 (Item 9 from file: 357) Links

Author: SHI Y; SUI G Patent Assignee: SHI Y; SUI G 2003 Patent Number: US 20030180756 Patent Date: 20030925 WPI Accession No.: 2003-852231 (200379) Priority Application Number: US 301516 Application Date: 20021121 National Application Number: US 301516 Application Date: 20021121 Language: English

Abstract: ... NOVELTY - A new nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter sequence; a first target sequence that is essentially complementary to a sequence of a target nucleic acid or its complement; a spacer sequence; a second target sequence that is essentially complementary to the first target sequence; and an RNA polymerase termination signal, where an RNA transcribed from the nucleic acid can....an RNA comprising the following nucleotides equences in a 5'-3' order: a first target sequence of about 19-25 nucleotides, which is at least about 95% identical to a portion of a nucleotide sequence of a target nucleic acid or its complement, a spacer sequence of about 5-10 nucleotides, a second target Page 35

cpgaacgtt.txt sequence of about 19-25 nucleotides that is essentially complementary to the first target seguence, and at least a portion of an RNA polymerase termination signal, target sequence, and at least a portion or an KNA polymerase termination signal; where the RNA inhibits expression of a target gene comprising a sequence that is essentially complementary to the first or the second target sequence; (2) a cell comprising the nucleic acid cited above; (3) a method for preparing a...signal comprises a number of thymidines sufficient for arresting Pol III activity. The first target sequence is at least about 9% identical to a nucleotide sequence of the target nucleic acid or its complement. The first target sequence is perfectly complementary to a sequence of a target nucleic acid or its complement the target sequence. nucleic acid is a target... ...the second target sequences comprise about 15-30, preferably 19-25 nucleotides. The first target sequence comprises a portion of the coding sequence of the target nucleic acid or its complement. The first and the second target sequences..... of thymidines sufficient for arresting pol III activity is 4 or 5 thymidines. The spacer sequence consists of about 3-15 or 5-10, preferably 6 nucleotides. The spacer sequence comprises a palindromic sequence. which is AACGTT. The Pol III promoter comprises a U6 promoter. The Pol III promoter comprises from about nucleotide -315 to about nucleotide +1 of the mouse U6 promoter having a fully defined sequence of 316 bp given in the specification. The nucleic acid is DNA, and is in......In the nucleic acid cited above, the polymerase is a restriction enzyme recognition sequence, a spacer sequence, a second restriction enzyme recognition sequence, and a number of thymidines sufficient for arresting Pol other, the first target sequence is perfectly complementary to a sequence of the target nucleic acid or its complement, and the polymerase termination signal target nucleic acid or its complement, and the polymerase termination signal consists of.....cell comprises providing the nucleic acid cited above, and introducing into the first restriction recognition sequence a first oligonucleotide of about 15-30 nucleotides comprising a sequence that is essentially complementary to a sequence of the target nucleic acid. The method further comprises introducing into the second restriction recognition sequence a second oligonucleotide of about 15-30 nucleotides that is essentially complementary to the sequence of the first oligonucleotide sequence. oligonucleotide. The first oligonucleotide comprises about 20-23 consecutive nucleotides of the target nucleic acid or its complement. The method further comprises introducing into the second restriction recognition sequence a second Comprises introducing a mucleotide sequence it ecognition for the control of the control of the control of the first of gonucleotide. Producing RNA molecules that inhibit expression of a target nucleic acid in a eukaryotic cell comprises introducing into a eukaryotic cell the nucleic acid down, where the first target sequence is essentially complementary to a sequence of the target nucleic acid or is complement, such that the nucleic acid is transcribed.....and produces RNA molecules that inhibit expression of a target nucleic acid. The first target sequence is perfectly complementary to a sequence of the target nucleic acid and the first and the second target sequences consist of... ...cell comprises introducing into a target cell the nucleic acid above, where the first target sequence is essentially or perfectly complementary to a sequence of the nucleic acid encoding the target protein or its complement, such that the nucleic.....introducing into the cell of the subject the nucleic acid above, where the first target sequence is essentially or perfectly complementary to a sequence of the gene encoding the target transcript. The resulting RNA was composed of two identical 21-nucleotide sequence motifs in an inverted orientation separated by a 6-bp spacer of non-homologous

Page 36

sequences...
E.C. Numbers:
Descriptors: RNA-polymerase promoter sequence, termination signal, target protein inhibition, adeno virus vector-mediated gene transfer expression in eukaryotic host.....disease, amyotrophic lateral sclerosis therapy, gene therapy cytostatic hemostatic virucide neuroprotective nootropic antiparkinsonian tumor protein sequence DNA sequence (23, 05)

? d s
Set s ltems Description
S1 256 S AACGTT
S2 32 S S I AND (LIP?)
S3 32 S S I AND (DIGONUCLEOTIDE OR ANTISENSE OR SEQUENCE OR DINUCLEOTIDE OR IMMUNOSTIMULATORY)
S4 56 RD (unique items)